Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Intelligent

Intelligent Monitoring Group Limited

Premium
Information Technology

Intelligent Monitoring Group is an Australasian security services consolidator that has transformed in three years from a sub-scale Perth alarm monitoring company (FY23 revenue A$24.3m) into the largest monitored security platform in Australia and New Zealand (FY26 revenue A$203.7m). Its core asset is the ADT brand licence and customer base in Australia and New Zealand, acquired from Johnson Controls in 2023. Around that core it has added a sequence of low-multiple bolt-on acquisitions in commercial integration, guarding, oil and gas security, and New Zealand fire protection (Wormald). Its main organic growth engine is ADT Guard, an AI-assisted remote video guarding product that replaces some manned guarding. Recurring revenue is about 53% of sales. The pending £180m acquisition of ADT UK Residential, again from Johnson Controls, would roughly triple pro forma EBITDA to about A$130m. It would also turn IMG into a leveraged, international, subscription-heavy security business. Execution and debt-servicing risk would rise accordingly. --- ### What the company does IMG provides monitored security, security integration, guarding and fire protection services to households, businesses, enterprises and government customers in Australia and New Zealand. The 1H26 half-year report groups revenue into three streams: 1. **Ongoing services**: recurring monitoring fees, service and maintenance contracts, and subscriptions. 2. **One-off services**: installation, project and integration work, and call-outs. 3. **Equipment sales**: alarm panels, cameras, access control hardware and related devices. By FY26, recurring revenue was about 53% of group sales (FY26 results commentary, per Investing.com via Parqet). ### Company's own description In its ASX materials, IMG describes itself as a provider of security, monitoring and risk-management services across Australia and New Zealand. Its stated goal is to build a large, profitable industrial services company with recurring revenue at its centre. Management's language in the FY25 and FY26 materials stresses three things: - the defensive, cash-generative nature of monitoring revenue; - the opportunity to move commercial customers from manned guarding to video-led solutions (ADT Guard); - a disciplined acquisition program that buys businesses at low single-digit EBITDA multiples, often non-core assets from Johnson Controls International (JCI). ### Independent characterisation IMG is best understood as a buy-and-build consolidator of security services with a subscription core, run by a board made up of capital-markets professionals rather than career security operators. Chair Peter Kennan is a former UBS investment banker. Managing Director Dennison Hambling is a former fund manager at Cooper Investors, First Samuel and 360 Capital. The playbook has three parts: 1. Buy under-managed ADT/Tyco assets from JCI at low multiples. Examples: about 4x for Tyco NZ/Red Wolf and 4.2x forecast EBITDA for ADT UK. 2. Run them as standalone, locally managed businesses. 3. Lift profitability through cost discipline, cross-selling commercial products, and replacing labour-intensive guarding with remote video monitoring. The model has delivered EBITDA scale quickly: Adjusted EBITDA rose from A$32.2m in FY24 to A$44.0m in FY26. Statutory profitability has lagged badly because of interest, amortisation of acquired customer contracts, impairments and transaction costs. FY26 was the first year of a small statutory profit (A$1.0m). ### Revenue model mix | Revenue type | Description | FY26 share | |---|---|---| | Subscription / recurring monitoring | Monthly monitoring fees (residential and commercial), ADT Guard subscriptions, contracted service and maintenance (including Wormald fire service contracts from June 2026) | About 53% (company) | | Services (non-recurring) | Installations, integration projects, call-outs, guarding contracts | Not separately disclosed | | Product / equipment | Alarm panels, cameras, access control and intercom hardware | Not separately disclosed | | Licensing | IMG is a licensee of the ADT brand in ANZ, not a licensor | Not applicable | ### Value chain position IMG works at the service delivery and monitoring layer of the security value chain. It does not manufacture hardware; it sources panels, cameras and devices from third-party vendors (the vendors are not disclosed). It owns and operates monitoring centres, field technician networks and, through acquisitions, guarding and fire-service workforces. The ADT brand gives it a consumer-facing marketing asset. The commercial integration businesses it acquired (ACG, AAG, KOBE, DVL) put it into design-and-install work for enterprise and government customers. ### Customer types and end-markets | Customer segment | Products used | Commentary | |---|---|---| | Residential households | ADT monitored alarms, smart home, self-install kits | At the ADT ANZ acquisition (2023), about 45% of monitoring revenue came from households (Channel News) | | Small and medium business | Monitored alarms, CCTV, access control | About 45% of monitoring revenue at acquisition | | Medical centres | Monitoring services | About 10% of monitoring revenue at acquisition | | Enterprise and blue-chip commercial | Integrated security (access control, IP CCTV, building automation), ADT Guard | Expanded via ACG/AAG (2024) and KOBE (2025) | | Government and defence | High-security systems (Red Wolf, ACG government clients) | Red Wolf serves Wellington government, council and military customers | | Resources (oil and gas) | Site security services | Western Advance (WA), acquired Sep 2025 | | Commercial buildings (NZ) | Fire protection, suppression and servicing | Wormald services about 28% of NZ commercial buildings (company, per Quartr) | | UK households (pending) | ADT UK Residential monitored security | More than 160,000 direct customers |

Revenue$0.1B
Employees600
Market CapN/A
Founded1993
East Perth, Australia

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Integrated

Integrated Research Limited

Premium
Information Technology

Integrated Research is a 38-year-old Australian enterprise-software company whose single platform, Prognosis, provides real-time observability for three niche but mission-critical domains: - unified communications and contact-centre ecosystems ("Collaborate"); - card, high-value and real-time payments environments ("Transact"); - HPE NonStop fault-tolerant infrastructure ("Infrastructure"). Its customers are among the world's largest banks, card processors, telecommunications carriers and Fortune 500 enterprises. JPMorgan Chase, for example, has been a client for about 30 years. Revenue is dominated by multi-year term licences recognised upfront, so statutory results swing with the size of each year's renewal book. After a decade of structural decline in its on-premise UC franchise, IR has pivoted under CEO Ian Lowe (since October 2024) to a "product-led growth" strategy. That strategy centres on AI-native products (the Iris assistant and IR Labs' Agentic SQA), observability-as-a-service (Prognosis Elevate) and utilisation-based pricing. The company is debt-free and holds cash roughly equal to its market capitalisation. It is, however, shrinking: FY26 statutory revenue fell 16% to A$57.6m. --- ### Company's own description (FY26 Annual Financial Report, paraphrased) The FY26 Directors' Report describes IR's principal activities as designing, developing, implementing and selling software that monitors, in real time, the performance of business-critical computing, including UC networks and payment networks. Prognosis is described as an integrated monitoring and management suite. It gives management and technical staff operational insight into, and helps them optimise: - HP NonStop systems; - distributed servers; - UC and payment environments; - the business applications running on those platforms. The product is built on a fault-tolerant, highly distributed architecture designed for functionality and scalability. IR reports serving clients in more than 40 countries. It sells through direct sales operations in the USA, UK, Germany, Singapore and Australia, plus a global channel network. Its customer base includes banks, credit-card companies, telecommunications carriers, technology companies, service providers and manufacturers. The company's current tagline (FY26 market announcements) describes IR as a leading global provider of observability for business-critical IT ecosystems, powered by Prognosis across multi-vendor infrastructure, UC&CX and payments. ### Business model and revenue model | Revenue stream | Recognition | FY2026 (A$m) | % of FY26 revenue (computed) | |---|---|---|---| | Licence fees (term licences, 1–5 years) | Point in time, on delivery of licence key | 38.8 | 67.3 | | Maintenance fees | Ratably over the support term (1–5 years) | 11.6 | 20.2 | | Subscription (SaaS / hosted) fees | Ratably over the term | 1.8 | 3.2 | | Testing solution services | Over the service period | 2.1 | 3.6 | | Professional services | As rendered / milestones | 3.3 | 5.7 | | Total | — | 57.6 | 100.0 | IR generates revenue from five statutory streams (FY26 Annual Financial Report, Note 3): The model has five characteristic features. 1. **Product vs. service vs. subscription vs. licensing mix.** - IR is economically a recurring-revenue business: 92% of FY26 pro forma revenue was secured through term-based contracts (FY26 Investor Presentation). - However, it is accounted for as predominantly a licence business. About two-thirds of statutory revenue is term-licence fees recognised upfront. - Pure SaaS/subscription revenue is small (A$1.8m in FY26, down 54% year on year). 2. **Pro forma revenue.** - Management's preferred measure restates term licences on a straight-line, over-time basis. - FY26 pro forma revenue was A$65.8m, against statutory revenue of A$57.6m. 3. **Total Contract Value (TCV).** - TCV is bookings net of residual value from prior related contracts. It was A$54.3m in FY26, made up of: - renewals: A$38.5m - new business: A$10.9m - services: A$4.9m 4. **Extended payment terms.** - IR commonly grants customers multi-year payment terms (1–5 years). - It discounts the transaction price, recognising a financing component as finance income. - This is why receivables (A$58.2m at 30 Jun 2026, including A$22.3m non-current) are very large relative to revenue. 5. **New utilisation-based (usage) models.** - Introduced in FY26 for the new AI products, under which clients pay by consumption rather than upfront commitment (FY26 Investor Presentation). ### Value-chain position IR is an independent software vendor (ISV) in the IT operations / observability layer. It sits above the underlying platforms: - HPE NonStop servers; - payment switches such as ACI's payment software; - UC/contact-centre platforms from vendors such as Microsoft, Cisco and Avaya. It monitors and correlates their telemetry. IR does not own the platforms it monitors, so its value depends on platform-vendor ecosystems and on the gap between native vendor tooling and enterprise multi-vendor needs. ### Customer types and end-markets Per the FY26 Investor Presentation, IR's clients are concentrated in: - technology and telecommunications (leading telcos); - banking, financial services and insurance (leading US banks); - health, government and education; - retail and industrial (Fortune 500 companies and large enterprises). New-client wins in FY26 included large US Government agencies and clients in health and finance. ### Independent characterisation IR is best understood as a mature, cash-generative niche-monitoring franchise with three distinct sub-businesses: **Infrastructure (HPE NonStop):** a highly cash-generative but mature, ex-growth installed base. Management said exactly this in the FY24 Annual Report. **Transact (payments):** a small but strategically valuable franchise among top-tier banks and processors. It was the only product line to grow statutory revenue in FY26 (+18%), driven by early renewals. **Collaborate (UC&CX):** the historical growth engine, now in structural decline as enterprises migrate from on-premise UC to SaaS platforms with native monitoring. Collaborate's constant-currency net revenue retention was 83% in both FY25 and FY26. The product-led growth (PLG) pivot is effectively an attempt to build a second-generation, AI-enabled and usage-priced product set on top of the trusted data position Prognosis holds inside client environments, before the legacy base erodes further.

RevenueN/A
Employees138
Market CapN/A
Founded1988
Sydney, Australia
Wrkr

Wrkr Ltd

Premium
Information Technology

Wrkr Ltd is a small-cap Australian regulatory-technology ("regtech") business. It sits in the plumbing between employers, payroll software, superannuation funds and the Australian Taxation Office. Its platform turns the regulated "moments of compliance" in a worker's life into digital, API-driven workflows: onboarding, Single Touch Payroll reporting, SuperStream messaging, super contributions clearing, SMSF contribution compliance and, since February 2026, pre-pay-run payroll assurance through PaidRight. Wrkr monetises through four streams: platform licence and development fees paid by fund administrators, chiefly MUFG Retirement Solutions; per-transaction clearing-house and gateway fees; interest earned on client money held in trust during settlement; and SaaS subscriptions. Its investment case rests on the Payday Super reform, which took effect on 1 July 2026. All six funds Wrkr administers via MUFG, including AustralianSuper and Rest, are live on the platform. The strategic question for 2026–27 is execution: converting 111,000 contracted organisations and a 5m-user target into recurring revenue before its funding runway is tested again. --- ### Company's own description (FY2026 Annual Report) The FY26 Annual Report describes Wrkr as an Australian regtech business that helps employers simplify workforce compliance across the "hire-to-retire" lifecycle. It provides digital solutions for employee onboarding, payments, super contributions, SMSFs and, after the PaidRight acquisition, payroll compliance and assurance. The company says it digitises compliance by collecting, transferring, analysing and processing data and payments between HR and payroll providers, accountants, advisers, banks, super funds, regulators and the ATO (S1, "Corporate overview"). The FY26 Directors' Report lists four principal activities: 1. **Wrkr PLATFORM.** A cloud compliance platform for messaging with the ATO, SuperStream, Single Touch Payroll (STP) 2.0, PEPPOL e-invoicing, Standard Business Reporting (SBR) and state authorities. It also orchestrates payment processing of pay and super contributions for fund administrators. 2. **Wrkr PAY.** A superannuation gateway and clearing house that processes employee pay and super contributions for payrolls and super funds. It includes interest earned on clearing-house funds held on trust, and the Wrkr SMSF Hub, which provides ATO messaging and contribution compliance for SMSFs. 3. **Wrkr READY.** A white-label onboarding product for full-time and casual workers. 4. **Wrkr PaidRight.** A payroll-compliance system that lets payroll, finance and HR teams review a whole payroll before pay is released, with workflow tools to fix issues. The company also holds a payment-processing patent in the USA. ### Business model and revenue model | Revenue type | Mechanism | FY26 A$k | % of total revenue | Recognition | |---|---|---|---|---| | Platform licence, development and support (Wrkr Platform) | Milestone-based development and implementation fees, plus ongoing licence and support and maintenance from fund administrators (MUFG) and payroll clients | 6,450 | 39.8% | Mostly over time | | Transaction and service fees (Wrkr Pay, including SMSF Hub) | Per-transaction clearing and gateway fees, SMSF Hub subscriptions | 5,512 | 34.0% | Transactions at a point in time; services over time | | Interest on restricted client trust funds | Float income on contributions held during the standard 3-day settlement cycle (average rate 3.87% in FY26, 4.28% in FY25) | 2,860 | 17.6% | Accrual (effective interest) | | SaaS / remediation (Wrkr PaidRight) | Payroll-compliance SaaS and legacy remediation services, consolidated from 5 Feb 2026 | 1,401 | 8.6% | Over time / point in time | | Wrkr Ready | Onboarding transactions | 0 | 0.0% | Point in time | | Total revenue from continuing operations | — | 16,223 | 100% | — | Wrkr earns revenue in four ways. FY26 shares are derived from S1 Note 5 and the P&L. By timing, FY26 service fees split into A$8.95m recognised over time (67%) and A$4.41m at a point in time (33%) (S1 Note 5). **Independent characterisation.** Wrkr is best described as a B2B2C compliance-infrastructure provider that sells mainly through intermediaries. **Channel structure:** The dominant channel is the fund administrator. MUFG Retirement Solutions (formerly Link Group's Australian Administration Services) holds the Master Services Agreement and white-labels Wrkr to its trustee clients: AustralianSuper, Rest, BUSSQ, LegalSuper, NESS Super and Prime Super. A second channel is cloud payroll and HCM vendors (28 payroll clients in FY26). A third, smaller channel is direct sales: the Wrkr small-business clearing house, the SMSF Hub and PaidRight enterprise customers. **Value-chain position:** Wrkr is a middleware and messaging layer. It is upstream of fund registries and downstream of payroll software and employer bank accounts, and it is an ATO-accredited SuperStream Gateway on the Superannuation Transaction Network (STN) (S1 risk section). **Mix shift:** In FY24–FY25, Wrkr Pay transaction fees and float income were the largest pool. In FY26, platform implementation revenue from MUFG and the funds overtook them. Management's stated objective is to convert this one-off implementation revenue into recurring per-user and per-transaction revenue as employers adopt Payday Super (S1 Chair/CEO report). **Customer types:** Super fund trustees (via the administrator), fund administrators, payroll and HCM software providers, employers from SMB to enterprise, SMSF trustees and their accountants/administrators, and payroll, finance and HR teams (PaidRight). **End-markets:** Australian superannuation contributions processing; employer payroll and STP compliance; SMSF administration; payroll assurance and wage-underpayment prevention; and, marginally, Hong Kong ORSO scheme administration through a MUFG implementation. ### Concentration Two customers each generated more than 25% of revenue in FY26. In FY25, two customers each generated more than 20%, and in FY24 two customers each generated more than 25% (S1, S2 Note 4). The customers are not named in the notes. From the context of the MSA disclosures, MUFG Retirement Solutions is almost certainly one of them; this is an analyst inference.

RevenueN/A
Employees66
Market CapN/A
Founded2016
Sydney, Australia
Integral

Integral Diagnostics Limited

Premium
Information Technology

Integral Diagnostics is an Australasian diagnostic imaging services group operating 142 clinics (62 of them "comprehensive" full-modality sites) across Victoria, Queensland, Western Australia, Tasmania, South Australia and New Zealand, supported by 468 reporting radiologists and a fast-growing teleradiology arm, IDXt. Following its December 2024 scrip merger with Capitol Health, IDX describes itself as having the second-largest clinic network in Australia, with roughly a 12% share of the national diagnostic imaging market and around 19% in its key operating states. Revenue is overwhelmingly derived from fee-for-service imaging reimbursed by Medicare plus patient gap fees, supplemented by hospital reporting contracts and teleradiology. Its differentiating claim is a "medical leadership model" that embeds radiologists in governance, including a radiologist on the board. In FY26 it generated A$788.7m of revenue, A$164.8m of operating EBITDA (20.9% margin) and A$47.4m of operating NPAT, and is now in a leadership transition under new CEO Jason Martinez. --- ### Company's own description (FY26 Annual Report, paraphrased) IDX describes itself as a leading provider of medical diagnostic imaging services in Australia and New Zealand that uses non-invasive imaging technologies to create images of bones, tissues and organs to diagnose and treat illness and injury. Its modalities are MRI, nuclear medicine (including PET), CT, mammography, ultrasound and radiography (X-ray and EOS). It serves referrers — general practitioners, dental practitioners, medical specialists and allied health professionals — and their patients. Comprehensive sites offer the full modality range and are generally located with or near major specialist referrers who require higher-complexity imaging. Its stated vision is "a healthier world" and its purpose is to deliver the best health outcomes for patients; its corporate tagline is that good medicine is good business. ### Independent characterisation IDX is a capital-intensive, labour-intensive, reimbursement-driven healthcare services business. The economic engine is: (1) referral capture from GPs and specialists; (2) conversion of referrals into imaging examinations on owned equipment; (3) radiologist reporting; and (4) billing to Medicare (bulk-billed) or Medicare plus a patient out-of-pocket gap. Three structural profit levers dominate: 1. **Modality mix.** CT, MRI and PET carry far higher fees per exam than X-ray and ultrasound. IDX's average fee per exam in Australia rose 6.5% in FY26 against Medicare indexation of only 2.4%, the difference being mix shift toward higher-end modalities (FY26 Annual Report). 2. **Radiologist productivity.** Radiologists are the scarcest and most expensive input. Teleradiology (IDXt, ~15% of scans) and AI tools (~10% of scans) are deployed to raise reports per radiologist (FY26 Annual Report, Industry and Regulatory Outlook). 3. **Fixed-cost leverage.** Rent, equipment and staffed rosters are largely fixed; incremental volume through existing sites expands margin. Group operating EBITDA margin moved from 19.3% (FY23) to 20.9% (FY26). ### Revenue model mix | Revenue stream | Description | Disclosure status | |---|---|---| | Fee-for-service imaging (Medicare + patient gap) | Core revenue; Medicare Benefits Schedule rebates plus out-of-pocket fees; bulk billing for some patients | Dominant; exact % not publicly disclosed | | Reporting contracts | Fixed-rate or per-report contracts with hospitals (public and private) | Included in "average fees per exam (including reporting contracts)"; separate revenue not disclosed | | Teleradiology (IDXt) | Urgent, routine and overflow reporting for IDX, private practices and public hospitals across all Australian states and NZ | Revenue not separately disclosed; reported ~15% of IDX Australian revenue at FY24 (FY24 Results release); reporting volumes up >30% in FY26 | | National Lung Cancer Screening Program (NLCSP) | Government-funded low-dose CT screening from 1 Jul 2025 | ~14% national share of screens in FY26; revenue not disclosed | | New Zealand private and publicly outsourced imaging | Private insurance, ACC, self-pay and public outsourcing (NZ has no Medicare equivalent) | NZ revenue not separately quantified in sources reviewed | There is no product, subscription or licensing revenue of significance; IDX is a pure services business. ### Value-chain position IDX sits in the provider layer: it buys equipment (from global OEMs such as Siemens Healthineers, GE HealthCare, Philips, Canon — specific supplier contracts not disclosed), leases premises (right-of-use assets A$228.5m at 30 Jun 2026), employs clinical staff, and bills payers. It does not manufacture equipment or develop software at scale. ### Customers and end-markets | Customer / referrer type | Role | |---|---| | General practitioners | Largest referral base, especially legacy Capitol (Melbourne metro community imaging); sensitive to GP attendance trends | | Medical specialists (orthopaedic, oncology, cardiology, neurology, breast) | Drive high-acuity CT/MRI/PET volumes at comprehensive sites | | Dental practitioners | OPG/cone-beam dental imaging | | Allied health (physiotherapists etc.) | Musculoskeletal imaging | | Hospitals (public and private) | Reporting contracts, co-located practices (e.g., Eastwood Private Hospital, Maroochy Private Hospital) | | Elite sport | Imaging @ Olympic Park (Melbourne) musculoskeletal centre of excellence | | Patients | 1.757m patients seen in FY26; 4.099m exams | | Referrer count | >70,000 referrers in FY26 |

RevenueN/A
Employees3,049
Market CapN/A
Founded2008
East Melbourne, Australia
Intega

Intega Group Limited

Premium
Information Technology

Intega Group was a mid-cap Assurance, Testing, Inspection and Certification (ATIC) platform focused on infrastructure and energy assets across Australia, New Zealand, the United States and Canada. It combined four specialist brands under one listed vehicle. Construction Sciences provides construction materials testing and geotechnical services to Australian and New Zealand infrastructure projects. Raba Kistner provides geotechnical engineering, CMT, project management and inspection in Texas and the US South-West. T2 Utility Engineers provides subsurface utility engineering in North America. PPI Quality & Engineering provides quality assurance to the oil, gas and renewable energy sectors. Intega was spun out of Cardno in October 2019 with Crescent Capital Partners as a majority shareholder. It spent two years cutting overhead and fixing underperforming units such as T2, which lifted underlying EBITDA margin from 12.8% to 17.2% of fee revenue. The board then ran a strategic review that ended in a A$0.90/share cash takeover by Dutch TIC group Kiwa. Today it is Kiwa's beachhead in infrastructure TIC in Asia Pacific and the Americas, a role reinforced by Kiwa's 2026 move for CSA Group's TIC business. --- **Company's own description.** In its FY21 results presentation (August 2021), Intega described itself as a leading ATIC business. It said it provided construction materials testing (CMT), subsurface utility engineering services (UES) and quality assurance for energy companies (QA). In the scheme implementation announcement (17 December 2021), Intega described itself as a leading engineering services provider focused on Asset and Infrastructure Integrity. At the time of acquisition, Kiwa called Intega a provider of ATIC services focused on the infrastructure and energy sectors. **Independent characterisation.** Intega was a labour-intensive, project-linked technical services business. It earned fees by placing qualified technicians, engineers and inspectors, together with field and laboratory equipment, on infrastructure, resources and energy projects. Its job was to verify that materials, ground conditions, buried utilities and fabricated assets met specification. It sits in the "T" and "I" of TIC, but with more engineering-consultancy content than a pure laboratory-testing house. Most revenue depends on public infrastructure capex: roads, rail, motorways, ring roads, level-crossing removals and pumped hydro. Mining infrastructure such as lithium projects and oil and gas capex add more cyclical exposure. **Revenue model.** Intega reported two revenue lines: **Gross revenue:** is total revenue for services provided, plus recoverable expenses. **Fee revenue:** is the portion of gross revenue that relates only to fees from services provided. Management used fee revenue as the base for margin calculations. In FY21, fee revenue was 74.7% of gross revenue (A$297.5m of A$398.1m). **Value-chain position.** Intega sits between asset owners and constructors on one side and design consultants on the other. It acts as an independent verifier during design (geotechnical investigation, utility mapping), construction (CMT, inspection, construction engineering and inspection) and operations (asset integrity, QA). Customers include state road and transport agencies, Tier 1 and Tier 2 contractors, utilities (for example Salt River Project in Arizona), miners, materials suppliers (Holcim) and oil, gas and renewables operators. **End-markets.** The end-markets are transport infrastructure (highways, motorways, ring roads), utilities, mining and resources infrastructure (for example Mount Holland Lithium), energy (pumped hydro such as Kidston; oil and gas; renewables), and building and construction.

RevenueN/A
Employees1,900
Market CapN/A
Founded1968
Newstead, Australia
Insurance

Insurance Australia Group Limited

Premium
Information Technology

Insurance Australia Group is the largest general insurer in Australia and New Zealand, underwriting A$18.4bn of gross written premium in FY26 through a portfolio of trusted consumer and commercial brands, led by NRMA Insurance (named Australia's most trusted insurance brand for 2025 by Roy Morgan), RACV and RACQ-branded insurance in Australia, CGU and WFI in commercial and rural lines, and AMI, State and NZI in New Zealand. Roughly 60% of premium is written through direct retail channels where IAG owns or controls the customer relationship, which underpins high retention and lower acquisition cost. The group has deliberately de-risked its earnings over five years through a 35% whole-of-account quota share, a multi-year natural perils volatility cover, exits from Asia, and a technology platform migration covering eight million retail policies. Its Ambition 2030 strategy targets A$25bn+ GWP, 15%+ ROE and high single-digit EPS growth, increasingly via motoring-club alliances and AI-enabled operations. --- ### What the company does IAG is a pure-play trans-Tasman general (property and casualty) insurance group. It manufactures, prices, underwrites, distributes and services short-tail personal lines (motor, home and contents, caravan, boat, motorcycle, landlord), short-tail commercial lines (commercial property, business packages, farm and rural, commercial motor and fleet, marine), and long-tail commercial classes (public and products liability, professional risks, compulsory third party in certain jurisdictions, and workers' compensation where it acts as agent or underwriter). It does not operate life insurance, health insurance or banking businesses. The company's own description in its FY26 results materials characterises IAG as the parent of a general insurance group with operations in Australia and New Zealand, underwriting over A$18bn of premium annually under leading brands including NRMA Insurance, RACV (under a distribution agreement with RACV), RACQ Insurance (under a distribution agreement with RACQ), CGU and WFI in Australia, and NZI, State, AMI and Lumley in New Zealand. Its stated purpose is "We make your world a safer place." ### Business and revenue model IAG's economic engine has four profit sources: 1. **Underwriting profit** — net earned premium less net claims, commissions and administration expenses. FY26 underwriting profit was A$1,306m (FY25: A$1,279m) on net earned premium of A$10,523m (FY26 Results Presentation, Appendix 1). 2. **Investment income on technical reserves** — the return on the ~A$7.6bn of assets backing policyholder liabilities. FY26: A$246m (FY25: A$464m), depressed by a A$136m negative mark-to-market from a rising risk-free rate. Underwriting profit plus this line equals the headline "insurance profit" (FY26: A$1,552m). 3. **Investment income on shareholders' funds** — the return on the ~A$6.3bn shareholders' funds portfolio. FY26: A$383m (FY25: A$403m), with growth-asset allocation lifted to ~28% (FY25: ~25%) and a ~A$460m alternatives sleeve. 4. **Reinsurance economics** — under the 35% whole-of-account quota share (effective 1 January 2026, up 2.5 points), IAG cedes premium and claims proportionally and earns ceding commissions and profit commissions; this materially reduces capital intensity and earnings volatility. FY26 quota share reinsurance expense was A$6,298m (FY25: A$5,631m), with non-quota-share reinsurance expense of A$1,337m (FY25: A$1,159m). In product/service/subscription/licensing terms, essentially 100% of revenue is "service" revenue in the form of annual insurance premiums (a renewable, quasi-subscription contract), plus investment income. There is no material product sale, licensing or fee-for-service revenue; fee-based business was a A$3m loss in FY26. ### Distribution and value-chain position IAG sits at the risk-carrying, manufacturing core of the general insurance value chain, but has integrated forwards into distribution (owned direct brands) and backwards into claims supply chain (an integrated motor repair and home-building supply network). The FY26 GWP mix by channel was approximately: Australian retail direct 51%, Australian retail partners 4%, Intermediated Insurance Australia 25%, NZ direct 9%, NZ partners 3%, NZI (NZ intermediated) 8% (FY26 Results Presentation, slide 8). Direct retail across both countries therefore represents ~60% of the premium pool. **Owned direct brands:** NRMA Insurance (national outside Victoria), ROLLiN', AMI, State. **Motoring-club alliances / distribution agreements:** RACV (Victoria, via the Insurance Manufacturers of Australia joint venture), RACQ (Queensland, 90% of RACQ Insurance acquired September 2025 with a 25-year exclusive distribution agreement), and the proposed RAC WA alliance (blocked by ACCC on competition grounds in September 2026; under public-benefit and Tribunal review). **Intermediated:** CGU (broker channel and underwriting agencies) and WFI (rural and small business via its own network) in Australia; NZI and Lumley in New Zealand. **Partners:** bank and affinity partners, notably New Zealand bank partners and Australian affinity partners (the Honey Insurance portfolio is being exited in FY27, removing ~A$150m GWP). ### Customer types and end-markets Customers are (a) Australian and New Zealand households (motor and home), which dominate the retail ~70% of premium; (b) SMEs, farmers and mid-market corporates (commercial short tail, the largest IIA line at A$2,723m in FY26); and (c) larger corporate and scheme clients for long-tail classes. End-markets are entirely domestic Australia (81% of FY26 GWP, derived) and New Zealand (19%, derived). ### Independent characterisation IAG is best understood as a scale-advantaged, brand-led, low-volatility personal-lines franchise with a profitable but cyclical commercial adjunct. Its structural edges are brand trust (NRMA, AMI), customer data scale, an integrated claims supply chain, and an unusually heavy reinsurance architecture that converts it into a "capital-lite" earnings stream more akin to a premium-servicing business than a balance-sheet-heavy risk taker. The trade-off is that a third of gross premium and profit is shared with reinsurers, and growth increasingly depends on acquiring motoring-club customer franchises — a strategy now running into competition-law limits in Western Australia.

RevenueN/A
Employees75
Market CapN/A
Founded1920
Sydney, Australia
Inspur

Inspur Digital Enterprise Technology Limited

Premium
Information Technology

Inspur Digital Enterprise Technology is the Hong Kong-listed enterprise-software arm of Shandong state-owned Inspur Group. It is a long-standing leader in China's large-enterprise ERP market. Its "Inspur Haiyue" (浪潮海岳) brand covers GS Cloud intelligent ERP, the iGIX PaaS/low-code platform, HCM, treasury, financial-shared-services and state-asset supervision software. Its customers are mainly central and provincial state-owned enterprises: 95 central SOEs, 23 provincial SASACs and more than 210 China Top-500 companies as of mid-2026. A second, lower-margin leg is data-centre engineering, now branded "intelligent computing centres", together with telecom OSS/BSS software through its Inspur Communications Information subsidiary. Since 2024 the company has repositioned around an "AI First" strategy built on its vertical Haiyue Large Model, agent clusters and the 2026 Mano Intelligent Execution System. Profitability peaked in FY2024 and fell sharply in FY2025–1H2026 as legacy software and telecom demand weakened. The shares have lost about 80% of their value from the September 2025 peak. --- ### Company's own description The FY2025 Annual Report describes the Company as an investment holding company. Its subsidiaries engage in "management software development, cloud services and sales of Internet of Things (IoT) solution". The 1H2026 announcement updates this to "enterprise AI, cloud services and management software and intelligent computing centers and others". Management says its goal is to become "a world-class provider of enterprise software, enterprise AI products, technologies and services". It serves enterprises' "full-business digital and intelligent transformation" along two dimensions: management digitalisation and production digitalisation (FY2025 Annual Report, Chairman's Statement and Future Outlook). ### Independent characterisation The Group is effectively three businesses in one listed shell: 1. **Large-enterprise application software and platforms (cloud services + management software).** This is the core franchise. GS Cloud ERP, the iGIX PaaS platform, HCM, treasury, financial sharing, supply chain, state-asset supervision and data platforms are sold mainly as large, project-based implementations to SOEs. The company reports these as "cloud services" when they are delivered in a cloud-native architecture or under cloud contracts. Inspur's reported "cloud" revenue is therefore largely project and licence revenue on a cloud-native stack, not multi-tenant SaaS subscription. This is a key difference from peers such as Kingdee, which report subscription ARR. Inspur does not disclose ARR or net dollar retention. 2. **Telecom operator software and services (Inspur Communications Information).** This covers OSS/BSS, network management, operation-and-maintenance support and low-altitude-network platforms, sold mainly to Chinese carriers and increasingly overseas (South Africa, Southeast Asia). The FY2025 Annual Report says this unit was named in a Gartner Magic Quadrant for BSS. Under the 2026 resegmentation it sits inside "cloud services and management software". 3. **Data-centre engineering and IoT solutions ("intelligent computing centres and others").** This covers EPC and M&E construction, liquid-cooling modules, operations and maintenance for data centres, plus vertical IoT solutions for grain storage, water and mining. It is high-revenue, low-margin (1–3% segment margin) and lumpy. A new Enterprise AI segment was carved out from 1 April 2026. It holds Haiyue Large Model, MaaS, Commercial AI and Industrial AI agent clusters and the Mano execution system. It is still loss-making. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model mix | Mostly project-based. Software implementation and licences, custom development, data-centre EPC and hardware pass-through (cost of inventories was RMB2,084m of RMB5,293m cost of sales in FY2025). Small but growing SaaS for SMEs (Inspur Ecloud, Mano Lite subscription). The subscription share is not publicly disclosed | | Value-chain position | Application-layer software vendor and systems integrator. Buys hardware and some software from Inspur Group fellow subsidiaries (purchase transactions RMB272m in 1H2026) | | Customer types | Central SOEs, provincial and municipal SOEs and SASACs, telecom operators (China Mobile and others), grain reserve agencies (Sinograin), banks, utilities, plus growth-stage SMEs and micro businesses | | Customer concentration | Low. The five largest customers were 11.74% of FY2025 turnover and the largest was 3.22% (2025 Annual Report). No customer exceeded 10% in FY2021–FY2023 | | SOE dependence | Broker First Shanghai (Oct 2025) says central and state-owned clients contribute over 80% of revenue and SME clients about 5% (secondary source) | | End-markets | Energy and power, construction, metals and mining, transport, grain storage, pharmaceuticals, chemicals, finance, telecoms, government (state-asset supervision) | | Geography | Overwhelmingly mainland China (99.6% of FY2023 revenue by customer location). Overseas is nascent: Indonesia, Malaysia, Thailand, South Africa, Algeria, Saudi Arabia |

Revenue$1.0B
Employees7,303
Market CapN/A
Founded1968
P.O. Box, Cayman Islands
Insignia

Insignia Financial Ltd.

Premium
Information Technology

Insignia Financial is one of Australia's largest diversified wealth managers, tracing its history to 1846 and today operating across the full wealth value chain: employed financial advice (Bridges, Shadforth), superannuation master trusts (MLC Super, MasterKey, Plum, IOOF Employer Super and ex-ANZ OnePath products), adviser wrap platforms (MLC Expand), and multi-asset and direct asset management (MLC Asset Management, including Antares fixed income and private equity co-investment programs). Built largely through acquisition—ANZ's Pensions & Investments business (2020) and NAB's MLC Wealth (2021)—it spent 2021–2025 integrating, separating from NAB and simplifying. Under CEO Scott Hartley, its "2030 Vision" aims to make it Australia's leading and most efficient diversified wealth company. Since April 2026 it has been privately owned by CC Capital and OneIM, which retained management and endorsed the 2030 strategy, removing public-market quarterly scrutiny while the company executes a multi-year Master Trust platform migration with SS&C. --- ### Company's own description In its standard boilerplate (FY25 results release, 21 August 2025; 1H26 presentation, 19 February 2026), Insignia describes itself as a leading Australian wealth manager, with origins dating to 1846, providing financial advice, superannuation, wrap platforms and asset management services to members, financial advisers and corporate employers. It characterises its four businesses as: employed advice (Bridges and Shadforth); Master Trust (one of Australia's largest superannuation and pension providers, used by large employers and independent advisers); Wrap (a contemporary technology platform for advisers and their clients); and Asset Management (multi-asset and single-asset-class capabilities run by investment teams in Australia, the USA and the UK). ### Business model and revenue model | Revenue type | Description | Approx. share of FY25 net revenue | |---|---|---| | Administration fees (Master Trust) | Member and administration fees on superannuation and pension accounts, charged as bps on FUA plus fixed dollar fees | c.52% (Master Trust segment net revenue A$735.5m) | | Platform fees (Wrap) | Administration fees on adviser-directed wrap accounts (MLC Expand and legacy wraps) | c.20% (A$283.2m) | | Investment management fees | Management and performance fees on multi-asset and direct capabilities | c.16% (A$218.7m) | | Advice fees | Ongoing and initial advice fees from Bridges/Shadforth clients; residual insurance commissions | c.11% (A$160.6m) | | Corporate / other | Small residual, divestment gains/losses | c.0.5% (A$6.7m) | Insignia's revenue is overwhelmingly asset-based, recurring fee income expressed in basis points on funds under management or administration: Percentages derived from FY25 results release segment net revenue (A$1,404.7m group). This is a service/subscription-like model with no product-manufacturing or licensing component; revenue is highly sensitive to (a) market levels (driving FUA), (b) net flows, and (c) fee margins (structurally compressing). Importantly, the Asset Management business also manages A$129.4bn of multi-asset investment options whose revenue and cost are recognised in the Master Trust segment (1H26 presentation, segment note), so the true economic contribution of investment management is larger than the reported segment. ### Value chain position Insignia is vertically integrated across the Australian wealth value chain: advice (distribution) → platform/trustee administration (product) → investment management (manufacturing). This integration was the business model the Hayne Royal Commission (2018–19) critiqued for conflicts of interest; the group has since moved toward a more "open architecture" stance (e.g., spinning out self-employed advice via Rhombus Advisory in July 2024 and selling Godfrey Pembroke in 2024), retaining only employed, higher-value advice. ### Customer types and end-markets **Superannuation members:** (retail, personal, advised, and default/MySuper members), including over 700,000 MasterKey and Plum accounts migrated off NAB systems in the NAB separation (company media release, 2025). **Corporate employers:** (workplace super; Plum and MLC workplace products). **Independent and aligned financial advisers:** using MLC Expand and legacy platforms. **High-net-worth and mass-affluent clients:** of Bridges and Shadforth. **Institutional investors:** (fixed income mandates, private equity and reinsurance co-investment funds). **Independent characterisation:** Insignia is a scale incumbent whose franchise sits mostly in the legacy, advised and retail segments of superannuation—precisely the segments losing share to industry funds and specialist platforms. Its genuine growth engines are MLC Expand (wrap) and multi-asset managed accounts; its profit engine (Master Trust) is in managed decline in flow terms and depends on cost-out and repricing to defend retention. The transformation thesis is therefore a "simplify and harvest, then grow the challengers" model.

Revenue$0.9B
Employees1,300
Market Cap$2.5B
Founded1846
Victoria, Australia
Insecticides

Insecticides India Ltd.

Premium
Information Technology

Insecticides (India) Limited is a Delhi-headquartered, promoter-controlled, fully integrated Indian crop-protection company. It describes itself as a crop protection and nutrition company. It manufactures more than 20 technical-grade active ingredients and more than 130 branded formulations across insecticides, herbicides, fungicides, biologicals and plant-growth regulators. These are sold mainly under the four-decade-old "Tractor Brand" through 8,500+ distributors and about 70,000 retailers, reaching an estimated 7.5 million farmers. FY2026 revenue was INR 2,140 crore. That makes IIL a mid-tier domestic generics-plus-specialty player, roughly the size of Dhanuka Agritech and smaller than Rallis, PI, UPL or Bayer CropScience India. Its strategy rests on three levers. The first is "premiumisation": in-licensed patented molecules from Nissan Chemical (Japan) and Corteva Agriscience (USA), branded "Maharatna". The second is backward integration into technicals at Chopanki and Dahej. The third is an FMCG-style rural distribution model. Its main vulnerabilities are monsoon dependence, a long working-capital cycle, and a modest export base (~5% of sales). --- ### What the company does IIL develops, registers, manufactures and markets agrochemicals for Indian farmers, with a smaller institutional and export business. The value chain runs from technical synthesis (making the active ingredient) through formulation (turning the active ingredient into usable liquids, powders and granules), branding, distribution and farmer extension. The company says about 95% of its revenue comes from products it manufactures itself (Q1 FY27 investor presentation). ### Company's own description (paraphrased from FY26/Q1 FY27 disclosures) The company calls itself one of India's leading fully integrated crop protection and nutrition companies. It cites a portfolio of 20+ technical products and 130+ formulations, ownership of the "Tractor Brand", plants at Chopanki (Rajasthan), Samba and Udhampur (Jammu & Kashmir) and Dahej (Gujarat), and an upcoming facility at Sotanala (Rajasthan). It highlights technical synthesis plants at Chopanki and Dahej as a backward-integration advantage. It also describes in-house R&D, farmer education through the IIL Foundation, and a pan-India reach of 7.5 million+ farmers, 70,000+ dealers and 8,500+ distributors (Press Release, Q1 FY27, 11 Aug 2026). ### Business model and revenue model | Revenue channel | Description | Share of FY2026 revenue | Economics | |---|---|---|---| | B2C (branded formulations) | Branded crop-protection products sold through the distributor → retailer → farmer chain under Tractor Brand and sub-brands | 73% | Highest gross margin; premium sub-portfolio (Focus Maharatna + Maharatna) equals 58% of B2C | | B2B (institutional) | Sale of technicals and bulk formulations to other agrochemical formulators and marketers | 22% | Lower margin; used to absorb plant capacity and meet top-line goals in weak B2C seasons | | Exports | Technicals and formulations to ~22 countries on the back of ~182 international registrations, including from a 100% export-oriented SEZ formulation unit at Dahej | 5% | Early-stage; management targets ~10% share over 2–3 years | **Revenue model characterisation:** About 100% product sales. There is no material service, subscription or licensing revenue. In-licensing runs the other way: IIL pays partners such as Nissan and Corteva for the rights to market their molecules. In-licensed product revenue was about INR 46 crore in Q1 FY27 versus about INR 36 crore in Q1 FY26 (Q1 FY27 earnings call, per secondary summaries). ### Product category mix (B2C revenue, FY2026) | Category | Share | Function | |---|---|---| | Insecticides | 49% | Insect control in crops | | Herbicides | 37% | Weed prevention and control | | Fungicides | 10% | Fungal disease control | | Biologicals / PGR | 4% | Crop health and productivity | ### Customer types and end-markets **End-users:** Smallholder and mid-size Indian farmers growing paddy, wheat, cotton, maize, soybean, chilli, pulses, vegetables and horticulture crops. **Direct customers:** About 8,500 distributors (B2C), Indian and global agrochemical companies (B2B), and importers and distributors in about 22 countries (exports). **Seasonality:** Revenue is heavily skewed to the kharif (monsoon) season. Q1 (Apr–Jun) and Q2 (Jul–Sep) together produced about 62% of FY2026 revenue (INR 1,329 crore of INR 2,140 crore). ### Independent characterisation IIL is best described as a branded-generics domestic formulator that is moving into in-licensed specialty molecules and selective backward integration. It does not discover proprietary molecules at scale, unlike PI Industries or the multinationals. Its OAT Agrio JV is a discovery effort, but it has no disclosed commercial new chemical entity yet. Its competitive moat is distribution depth and brand familiarity in north and central India, plus cost advantage from captive technicals. The strategic thesis since FY2023 has been margin repair through mix. Gross margin rose from 23.1% (FY23) to 31.5% (FY26) as the premium share of B2C climbed from 51% to 58%. The thesis faced a stress test in FY2026–Q1 FY27: weather-driven demand weakness forced a higher B2B mix, and management cut guidance.

Revenue$0.2B
Employees1,531
Market CapN/A
Founded1996
Delhi, India
Austrax

Austrax Holdings Limited

Premium
Information Technology

| Field | Detail | |---|---| | Current legal name (English) | Austrax Holdings Limited | | Current dual foreign name (Chinese) | 南強控股有限公司 | | Former names | Innovax Holdings Limited; 創陞控股有限公司 | | Effective date of name change | 2 July 2026 (date of the Cayman Islands certificate of incorporation on change of name), approved by special resolution at the EGM of 22 June 2026 | | Stock short name | Changed from "INNOVAX HLDGS" to "AUSTRAX HLDGS" with effect from Monday, 10 August 2026 (HKEX trading arrangement notice) | | Website | Changed from www.innovax.hk to www.austrax.com (change-of-name announcement, 4 August 2026) | | Country of operations | Hong Kong SAR, China | | Exchange / ticker | Main Board of The Stock Exchange of Hong Kong; stock code 2680 (2680.HK / HKG:2680) | | ISIN | KYG4790R1092 as supplied. Not re-verified. A 10-to-1 share consolidation took effect on 25 October 2024; consolidations in Hong Kong often carry a new ISIN, so this code should be checked against HKEX/CCASS records | | CUSIP | Not applicable (no US listing); not publicly disclosed | The identification details supplied (Innovax Holdings Limited, HKEX 2680, website www.innovax.hk) are outdated. The entity has been renamed. ### Core corporate data | Field | Detail | Source | |---|---|---| | Founding year | 2014 (group established in Hong Kong) | Annual Report 2019/20; Annual Report 2025/26 | | Incorporation jurisdiction | Cayman Islands, exempted company with limited liability | All HKEX filings | | Registered office | Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands | Annual Report 2025/26 | | Headquarters and principal place of business in Hong Kong | Rooms 1201–1202 and 1212, 12/F, West Tower, Shun Tak Centre, 168–200 Connaught Road Central, Hong Kong. Address as at the Annual Report date | Annual Report 2025/26 | | Listing date | 14 September 2018 (Main Board); prospectus dated 31 August 2018 | Annual Report 2025/26 (Deed of Non-competition section) | | Fiscal year end | Last day of February | All annual reports | | Shares in issue | 60,000,000 ordinary shares (HK$0.10 par); authorised share capital 100,000,000 shares | Annual Report 2025/26; Monthly Return for September 2026 | | Controlling shareholder | Mr. Wang Tingfa, through Billion Shine International Investment Limited (BVI), holding 45,000,000 shares (75.00%); plus 39,825 shares (about 0.07%) acquired personally under the mandatory offer | Offer closing announcement, 29 April 2026 | | Chairman and CEO | Mr. Wang Tingfa (since 30 May 2026) | Change-of-directors announcement, 29 May 2026 | | Auditor | BDO Limited, Certified Public Accountants (Registered Public Interest Entity Auditor). No auditor change in the past three years | Annual Report 2025/26 | | Company secretary and CFO | Ms. Chau Lok Yi (company secretary since 4 May 2018; CFO since May 2017) | Annual Report 2025/26; announcement of 7 August 2026 | | Hong Kong branch share registrar | Union Registrars Limited (from 12 March 2025; previously Computershare Hong Kong Investor Services) | Annual Report 2025/26 | | Legal advisers | Jingtian & Gongcheng LLP (Hong Kong) | Annual Report 2025/26 | | Principal bankers | Bank of China (Hong Kong), Chong Hing Bank, Hang Seng Bank, HSBC | Annual Report 2025/26 | | Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Employees at year end (incl. executive directors) | 36 | 38 | 38 | FY2025 and FY2026 come from the Annual Report 2025/26. Female share of workforce at 28 February 2026 was about 34.2%. ### Market capitalisation | Date | Share price (HK$) | Market cap (HK$ M) | Basis | |---|---|---|---| | 9 Oct 2026 (delayed intraday quote) | 5.61 | 336.6 | 60,000,000 shares × price (analyst calculation; price per StockAnalysis.com) | Austrax Holdings is a micro-cap, Hong Kong-only boutique financial services group. It is licensed by the SFC for Type 1 (dealing in securities), Type 4 (advising on securities), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities. Its franchise rests on IPO sponsorship, financial and independent financial advisory, compliance advisory, equity placing and underwriting, retail and corporate brokerage, margin financing and a small but fast-growing asset management arm. Revenue from these activities is small (HK$22.7 M in FY2026) and highly cyclical. Reported earnings are driven mainly by gains and losses on the proprietary investment book rather than by fee income. In 2025–26 the group changed hands: founder Chung Chi Man sold his 75% stake to mainland investor Wang Tingfa for HK$270 M. The money lending and investment-holding subsidiaries were carved out to the founder, the board was replaced, and the group was rebranded as Austrax, with a stated focus on corporate finance advisory for Hong Kong and Greater China clients. --- ### The company's own description (paraphrased from the Annual Report 2025/26) The Annual Report 2025/26 describes the group as an integrated financial and securities services provider. It holds SFC licences for Type 1, Type 4, Type 6 and Type 9 regulated activities under the Securities and Futures Ordinance (Cap. 571). During FY2026 it also ran a money lending business under the Money Lenders Ordinance (Cap. 163). Its stated service range covers: - corporate finance advisory (IPO sponsorship, financial and independent financial advisory, and compliance advisory); - placing and underwriting; - securities dealing and brokerage; - securities financing; - research; - asset management; and - money lending. The money lending business was reclassified as a discontinued operation after the board approved its sale on 25 September 2025. The sale completed on 31 March 2026. The rebranding announcement of 29 May 2026 sets out the new owner's intended identity. The board said the Austrax name would give a fresh corporate image and better reflect the group's position as a dedicated local financial institution focused on corporate finance advisory services in Hong Kong and the Greater China region. ### Business model and revenue model The group is a pure services and balance-sheet business. It has no product, subscription or licensing revenue. Its income streams fall into three economic types: 1. **Fee-for-mandate advisory revenue (Type 6).** This covers IPO sponsorship (milestone-based fees over long project cycles), financial adviser and independent financial adviser (IFA) mandates under the Listing Rules and Takeovers Code, and compliance adviser retainers for newly listed issuers. In FY2026 this stream produced HK$9.9 M from 45 projects (7 IPO sponsorships, 29 FA/IFA mandates, 9 compliance advisory mandates). 2. **Transaction-based capital markets revenue (Type 1).** This covers placing, underwriting and sub-underwriting commissions on equity placings, IPO distribution and, in FY2025, bond issues. It is highly episodic. It fell from HK$151.5 M in FY2025 to HK$1.8 M in FY2026 after the group stopped bond underwriting. Brokerage commission (HK$5.3 M in FY2026) is also transactional and tracks Hong Kong market turnover. 3. **Spread and AUM-based revenue.** This covers interest on margin loans and IPO financing (HK$2.0 M in FY2026), asset management and fund management fees (HK$3.7 M in FY2026, on AUM of HK$216.3 M) and, until its disposal, money lending interest (HK$2.4 M in FY2026, reported in discontinued operations). A fourth, non-revenue earnings stream dominates bottom-line outcomes: realised and unrealised gains or losses on financial assets at fair value through profit or loss (FVTPL). In FY2026 the net realised FVTPL gain was HK$29.1 M and the net unrealised loss was HK$1.8 M. Together these exceeded the year's entire fee revenue (Annual Report 2025/26, MD&A). ### Value chain position The group sits at the small-cap end of the Hong Kong primary-market value chain. It sponsors and distributes IPOs for small and mid-size issuers, advises listed companies and their controllers on notifiable and connected transactions and takeovers, and acts as IFA to independent board committees. It then monetises the same client relationships through post-listing compliance advisory, follow-on placings, brokerage and margin financing. In FY2026 it acted as joint bookrunner and joint lead manager on one IPO. In FY2025 it acted as bookrunner and underwriter on 25 unlisted corporate bond issues. Much of the FY2025 bond underwriting revenue was passed on to sub-underwriters. Placing and underwriting revenue of HK$151.5 M was offset by HK$148.7 M of sub-underwriting expenses recorded in other operating expenses. The economic margin on that activity was therefore only about HK$2.8 M (analyst calculation from Annual Report 2025/26 figures). ### Customer types and end-markets | Customer type | Services consumed | Evidence | |---|---|---| | IPO applicants (Main Board and GEM) | Sponsorship, bookrunning, underwriting, IPO financing for retail subscribers | 7 IPO sponsorship mandates in FY2026 and FY2025; 1 IPO bookrunner role in FY2026 | | Hong Kong-listed issuers and their controlling shareholders | FA under Listing Rules and Takeovers Code; placing agent for new and existing shares | 21 FA mandates in FY2026 (FY2025: 23); 5 equity placing roles in FY2026 | | Independent board committees and independent shareholders | IFA opinions | 8 IFA mandates in FY2026 (FY2025: 6) | | Newly listed issuers | Compliance adviser | 9 mandates in FY2026 | | Retail and professional investors | Brokerage (HK and US equities), margin finance | 1,296 securities accounts at 28 Feb 2026 (28 Feb 2025: 1,003); margin loans HK$19.3 M | | Professional investors | Discretionary accounts and funds (via an SFC-registered open-ended fund company and the Innovax Alpha SPC fund) | AUM HK$216.3 M at 28 Feb 2026 (28 Feb 2025: HK$69.2 M) | | Individuals and corporates (until 31 Mar 2026) | Money lending | 11 personal loans and 2 corporate loans; loan receivables HK$32.6 M | Customer concentration is moderate. The five largest customers made up about 26.1% of FY2026 revenue and the largest single customer about 6.5% (Annual Report 2025/26). The group reports no major suppliers. ### Independent characterisation On the evidence, Austrax is a sub-scale, sponsor-led boutique and not an "integrated" financial group in any meaningful sense: - Recurring fee revenue (advisory plus brokerage plus asset management plus financing interest) was about HK$21 M in FY2026. - That sat against staff costs of HK$24.3 M and other operating expenses of HK$17.5 M. The core franchise is therefore loss-making before investment gains (S&P-basis operating income was -HK$20.4 M in FY2026). - Over FY2022–FY2026 the group reported a cumulative net loss of about HK$50.9 M (analyst sum of reported net income). Profitable years (FY2024, FY2026) coincided with gains on the proprietary book. Under a new controller, the investment case now rests on whether the platform's SFC licences, sponsor principal capability and track record can be redeployed into a larger Greater China-oriented corporate finance business. No business plan, targets or capital commitments have been disclosed so far.

RevenueN/A
Employees38
Market CapN/A
Founded2014
P.O. Box, Cayman Islands
INEOS

INEOS Styrolution

Premium
Information Technology

| Field | Detail | Source / Period | |---|---|---| | Legal name (group parent) | INEOS Styrolution Group GmbH | Company imprint / public registries | | Former names | Styrolution (2011–2015/16), the BASF–INEOS 50:50 JV. Predecessor INEOS business: INEOS NOVA, then INEOS Styrenics | INEOS Styrolution history page (2026) | | Founding | Letter of intent signed by INEOS and BASF in 2010; JV launched 2011 | INEOS Styrolution history page | | Incorporation jurisdiction | Germany (GmbH) | Registry | | Headquarters | Mainzer Landstraße 50, 60325 Frankfurt am Main, Germany | Motherbase profile (2024) | | Regional HQs | Aurora, Illinois, USA (Americas); Singapore (Asia) | Company boilerplate (2024) | | Ultimate parent | INEOS Group Limited (founder and chairman Sir Jim Ratcliffe) | Company boilerplate | | Intermediate reporting parent | INEOS Quattro Holdings Ltd (UK) | IQ TS 2021–2026 | | Stock exchange / ticker | None. Not listed | — | | ISIN / CUSIP (equity) | Not applicable | — | | Fiscal year end | 31 December | IQ TS | | Employees (latest) | ~2,600 | INEOS Styrolution "About us" (FY2025 data, viewed Oct 2026) | | Employees (trend) | ~3,600 (2021), ~3,100 (2022), ~3,000 (2023–2024), ~2,600 (2025) | Company boilerplates and careers pages | | Production sites | 14 (stated 2025/26); 13 once Channahon closes in Q4 2026 | About us page; Channahon release | | R&D centres | 6 | About us page | | Applications served | 2,000+ | About us page | | Customer reach | Customers in 106 countries (older portal figure) | ineos-styrolution.com portal | | Revenue FY2025 | EUR 3.9bn | About us page | | EBITDA FY2025 | EUR 285M (new definition) | IQ TS Q4 2025 | | Auditor | Not publicly disclosed at Styrolution level | — | | Market capitalisation | Not applicable (private) | — | | Website | https://www.ineos.com/businesses/ineos-styrolution/ | — | INEOS Styrolution describes itself as the world's number-one producer of high-performance styrenics. Its integrated portfolio runs from styrene monomer (SM) through polystyrene (PS) and ABS to advanced styrenic specialties such as SAN, ASA, SBC, MABS and ABS blends. It was formed in 2011 by combining the BASF and INEOS styrenics businesses. It became wholly INEOS-owned in 2014. It has since been reshaped into a smaller, more specialty-weighted and more Asia-exposed business. That reshaping has been driven by four things: - Acquisitions in Korea (K-Resin) and China (the former Total PS plants). - A 600 kt/yr ABS joint venture with Sinopec in Ningbo. - An extended programme of closures and divestments in structurally oversupplied commodity assets: Sarnia SM, Map Ta Phut, Wingles PS and Channahon PS. Revenue has fallen from about EUR 6.6bn (2022) to EUR 3.9bn (2025) and headcount from about 3,600 to 2,600. The business now competes on technology brands (Terluran®, Novodur®, Luran® S, Styrolux®, K-Resin®), recycled and bio-attributed ECO grades, and the world's largest single-train SM unit at Bayport, Texas. It operates inside a highly leveraged parent group. --- ### What the company does INEOS Styrolution manufactures and sells styrene-based thermoplastics and their monomer feedstock. Its value chain has four layers: 1. **Styrene monomer (SM).** SM is produced from benzene and ethylene via ethylbenzene dehydrogenation at US Gulf Coast sites (Bayport and Texas City) and at Antwerp. It is sold to third parties and consumed internally. 2. **Polystyrene (PS).** This covers general-purpose (GPPS) and high-impact (HIPS) grades for packaging, appliances, healthcare and construction. Production is in Europe (Antwerp, after the Wingles PS exit), the Americas (Decatur, Altamira; Channahon closing) and Asia (Ningbo, Foshan, Korea). 3. **ABS Standard.** These are acrylonitrile-butadiene-styrene grades (Terluran®, Lustran®) for automotive, electronics and household goods. Production is in Antwerp, Wingles, Cologne, Korea, Altamira and the Ningbo JV. 4. **Styrenic specialties.** This layer includes: - SAN (Luran®) and ASA (Luran® S) - Specialty ABS (Novodur®) - Styrene-butadiene copolymers (Styrolux®, Styroflex®, K-Resin®) - Transparent MABS (Terlux®) - SMMA copolymers (NAS®, Zylar®) - ABS/PA blends (Terblend® N) Brand names are from company product literature. Grade-level availability changes over time. ### Company's own description In 2025–2026 releases the company describes itself as the number-one producer of high-performance styrenics. It cites more than 90 years of materials-science innovation and full ownership by INEOS Group (Wingles release, 13 Nov 2025; Indaver release, 25 Sep 2025). Its "About us" page says it creates materials found in everyday life, from automotive and electronics components to medical devices and household appliances. Earlier boilerplates (2023–2024) emphasised investment in technology for closed-loop recyclability and lower carbon emissions. INEOS Styrolution does not publish a standalone annual report. The "latest annual report" description requested therefore relies on these official corporate statements. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | ~100% product sales of resins and monomer. No material subscription, service or licensing revenue is disclosed. Technology is contributed in kind to JVs: Terluran® technology underpins the Sinopec JV (2022 JV releases) | | Pricing | Largely cost-plus or formula-linked to benzene, ethylene, butadiene and acrylonitrile. Specialties carry value-in-use premiums. Inventory holding gains and losses are material to quarterly EBITDA (e.g., –EUR 38M in Q2 2025; +EUR 70M in Q2 2026; IQ TS) | | Value-chain position | Mid-stream. It buys benzene, ethylene, butadiene and acrylonitrile, and sells resin to compounders, converters, moulders and OEMs | | Customer types | Injection moulders, sheet and film extruders (e.g., Monguzzi furniture edge bands, July 2026), compounders, packaging converters, automotive tier-1s, appliance and electronics OEMs, medical device makers, toy makers | | End-markets | Automotive, electronics, household and appliances, construction, healthcare, packaging, toys/sports/leisure (company boilerplate) | ### Independent characterisation INEOS Styrolution is best understood as a cyclical, feedstock-spread business with a specialty overlay. Its earnings power swings with the SM–benzene/ethylene spread, the ABS–feedstock spread and inventory effects. EBITDA fell from EUR 1,180M (2021) to EUR 200M (2023), a decline of more than 80% in two years (IQ TS Q4 2021; IQ TS Q4 2023/2024). Since 2023, management has been engaged in "capacity triage": - Closing sub-scale or structurally uncompetitive commodity assets (Sarnia SM, Wingles PS, Channahon PS). - Selling non-core Asian specialty assets (Thailand). - Concentrating growth capital in China through a capital-light 50:50 JV structure. Specialties and circular materials (ECO grades, depolymerised SM from Indaver) are its differentiators. Commodity SM and PS remain the volume base and the main source of volatility.

Revenue$4.4B
Employees2,600
Market CapN/A
Founded2010
Frankfurt am Main, Germany
Indorama

Indorama Ventures Public Company Limited

Premium
Information Technology

| Attribute | Detail | Source / Note | |---|---|---| | Legal name | Indorama Ventures Public Company Limited | SET listing | | Former names | Operating predecessor: Indorama Polymers Public Company Limited (PET resin business). IVL became the listed holding vehicle in 2010. | (prior disclosure, not re-verified) | | Founding year | 1994 (group's Thai PET operations) | Company profile data (roic.ai); IVL marked its "35th anniversary" in the 2025 One Report, which dates group origins to about 1990 under a broader definition | | Incorporation jurisdiction | Kingdom of Thailand (public limited company); incorporated 2003 | (prior disclosure, not re-verified) | | Headquarters | 75/102 Ocean Tower 2, 37th Floor, Soi Sukhumvit 19, Bangkok 10110, Thailand | (prior disclosure, not re-verified) | | Primary listing | Stock Exchange of Thailand (SET), ticker IVL; NVDR line IVL-R | SET | | Other trading lines | OTC (US) INDO.Y; Frankfurt/Stuttgart NVDR line (I93 / A1CXKA) | Simply Wall St; Börse Stuttgart | | ISIN | TH1027010012 (ordinary shares) | Parqet | | CUSIP | Not applicable / n/v | No US primary listing | | Fiscal year end | 31 December | S&P / SET | | Shares outstanding | About 5,614.6 million ordinary shares (unchanged FY2021 to 2026) | S&P standardized balance sheet | | Employees (latest) | About 26,000 worldwide (company figure cited in Eurofound factsheet, March 2026); "more than 25,000" (Eurofound, May 2026) | Eurofound ERM 204357 / 300431 | | Employees (3-year trend) | "Over 26,000" (2022, D&B profile) → about 26,000 (2026). Year-by-year audited headcount n/v; IVL 2.0 included headcount reductions in 2025 per Q2 2025 commentary | D&B; Parqet / investing.com summary | | Auditor | KPMG Phoomchai Audit Ltd. | (prior disclosure, not re-verified for FY2025) | | Share price | THB 27.75 (close, 6 October 2026) | SET quote page | | Market capitalisation | About THB 155.8 billion (5,614.6m shares × THB 27.75), about USD 4.7 billion at about THB 33/USD | Calculated | | Website | www.indoramaventures.com (beta.indoramaventures.com hosts newer releases) | Company | | Controlling shareholder | Indorama Resources Ltd. (Lohia family vehicle), majority holder | DAOL Securities shareholder table; exact 2026 % n/v | | Group CEO | Aloke Lohia (Vice Chairman and Group CEO) | IVL releases | | Chairman | Sri Prakash Lohia (Non-Executive) | IVL board disclosure | | Credit rating (domestic) | TRIS Rating: company rating AA-; outlook revised to Negative (2024). 2025 to 2026 rating actions n/v | TRIS Rating | | Manufacturing footprint | 117 manufacturing locations in 31 countries (pre-2025 baseline, before ongoing closures and divestments) | World Economic Forum organisation profile | Indorama Ventures is the world's largest integrated producer in the polyester and PET value chain and a leading global maker of surfactants and technical fibres. Its operations span Asia-Pacific, the Americas, Europe and Africa. The group converts US shale-advantaged ethane and global aromatics into intermediates (PTA, MEG, EO), PET resin and recycled PET. It then extends downstream into rigid packaging (Indovida), specialty surfactants (Indovinya) and fibres for hygiene, mobility and lifestyle markets. Its core proposition is "local-for-local" supply to global consumer brands, backed by scale, integration and a large recycling platform that has processed more than 166 billion PET bottles. After a three-year cyclical trough (2023 to 2025) marked by Chinese overcapacity, cumulative net losses and leverage above 9x net debt to EBITDA, IVL has spent the IVL 2.0 programme closing Western assets and cutting fixed costs. It now targets a doubling of EBITDA by 2028. A sharp 2Q26 spread recovery returned the group to profit. --- ### What the Company Does IVL is a vertically integrated petrochemical and materials company. Under its current four-segment structure (in place since 1Q25, when Indovida was carved out of Combined PET), it operates as follows. 1. **Combined PET (CPET)** is the core engine. It produces PET resin (commodity and specialty high-value-added grades), recycled PET (rPET), and the upstream intermediates PTA, PIA, MEG and EO. Through its US Gulf Coast assets it also produces ethylene and MTBE. CPET earns a "spread" between feedstock (paraxylene, ethane/ethylene) and PET/intermediate selling prices. In 1H26 it generated roughly two-thirds or more of group EBITDA. 2. **Indovida (Packaging)** converts PET resin into preforms, closures and bottles for beverage and FMCG brand owners, mainly in emerging markets. It is in the process of merging into EPL Limited (India), which would make IVL the 51.8% promoter of a listed, multi-format packaging company. 3. **Indovinya (Surfactants / specialty chemicals)** was formed from the Huntsman chemical intermediates and surfactants acquisition (2020) and the Oxiteno acquisition in Brazil (April 2022). It sells ethoxylates, amines, glycol ethers and specialty surfactants into home and personal care, crop protection, coatings, and energy and resources. Its business is split into High Value Applications (HVA) and Essentials. HVA contributed about 80% of Indovinya EBITDA in 2Q26. 4. **Fibers** produces polyester, polyolefin and nylon fibres and yarns across three verticals: Hygiene (nonwovens inputs), Mobility (tyre cord, airbag and safety yarns) and Lifestyle (apparel and home textiles, including Trevira flame-retardant fibres). ### Business and Revenue Model | Revenue model element | Characterisation | |---|---| | Product vs. service | Almost entirely product sales (physical chemicals, resins, fibres, packaging). Service, subscription and licensing revenue is negligible or not separately disclosed. | | Pricing mechanism | Largely cost-plus and spread-based. Many PET and intermediate contracts pass through raw-material costs (paraxylene, MEG, ethylene) with a conversion margin, so reported revenue swings with oil and feedstock prices even when margins are stable. | | Margin driver | Industry spreads (for example, the China integrated PET spread rose to USD 279/t in 2Q26 from USD 176/t in 1Q26 per CLSA), import parity in Western markets (ocean freight, tariffs), operating rates, and mix of High Value Added (HVA) products. | | Inventory effect | IVL reports "Adjusted" or "Core" EBITDA before inventory gains and losses because rising or falling feedstock prices create sizeable stock gains or losses (for example, a THB 779 million inventory loss in 2Q25 per DAOL). | | Volume | Group sales volume was about 3.1 to 3.6 million tonnes per quarter in 2024 to 2025 (3.64 MMT in 2Q24; 3.3 MMT in 2Q25; 3.1 MMT in 4Q25). | ### Value-Chain Position | Stage | IVL assets / products | |---|---| | Feedstock / olefins | US ethane cracker at Lake Charles, Louisiana (ethylene), which gives a shale-gas cost advantage | | Intermediates | PTA, PIA, MEG, EO, MTBE | | Polymers | PET resin (virgin and recycled), specialty PET | | Downstream conversion | Preforms, closures and bottles (Indovida); fibres and yarns (Fibers); surfactant formulations (Indovinya) | | End-of-life | PET bottle recycling (rPET) and textile-to-textile recycling (Jiaren JV) | IVL is positioned across upstream intermediates → midstream polymers → downstream converted products: ### Customers and End-Markets | End-market | Segment exposure | Customer type | |---|---|---| | Beverages and food packaging | CPET, Indovida | Global soft-drink, water and food brand owners and converters | | Home and personal care | Indovinya, Fibers (Hygiene) | FMCG majors and formulators | | Hygiene (diapers, wipes, feminine care) | Fibers (Hygiene) | Nonwovens producers | | Automotive and mobility | Fibers (Mobility), Indovinya | Tyre makers, airbag and seatbelt manufacturers | | Agrochemicals | Indovinya (crop solutions) | Crop protection formulators | | Coatings and industrial | Indovinya | Paint and coatings producers | | Energy and resources | Indovinya | Oilfield and mining chemicals customers | | Apparel, home and contract textiles | Fibers (Lifestyle) | Textile mills and brands | | Fuel additives | CPET intermediates (MTBE) | Refiners and blenders | ### Company Self-Description vs. Independent Characterisation **Company self-description (paraphrased from releases):** IVL describes itself as a global sustainable chemical producer with diversified international businesses integrated across the petrochemical value chain. It says its products serve daily necessities and that its local-for-local model gives resilience through the cycle. In the 1H26 release, management framed the key test as converting its platform advantages (scale, integration, global footprint, customer positions) into more consistent earnings, cash generation and returns through the cycle. **Independent characterisation:** In economic terms IVL is a cyclical, spread-driven commodity chemical company with a growing but still minority layer of specialty exposure (Indovinya HVA, specialty PET, technical fibres, packaging). Several features define its risk profile: - Exposure to Chinese PTA/PET overcapacity, which compressed benchmark spreads from 2023 to 2025. - A Western-heavy asset base. Management said in 2022 that about two-thirds of the portfolio sat in Western markets. This base benefits from import parity and tariffs but suffers from high European energy costs. - A balance sheet built during an acquisition-led era (2010 to 2022) that became over-levered when the cycle turned. The IVL 2.0 pivot is explicitly a shift from acquisition-led growth to cash-flow discipline.

RevenueN/A
Employees26,000
Market Cap$4.7B
Founded1994
Bangkok, Thailand
Indigo

Indigo Ag

Premium
Information Technology

Indigo Ag is a Flagship Pioneering-founded agricultural technology company. It began in 2013 as a plant-microbiome biotech and grew into one of the most heavily funded agtech ventures in the world. By 2018 it was valued at USD 3.5 billion, and it operated an expansive "five startups in one" model spanning microbial seed treatments, a grain marketplace, logistics, agronomy, and carbon. A sharp market correction followed, with layoffs, exits from grain and transport, and a reported valuation collapse of about 94% in 2023. Under CEO Dean Banks, Indigo then refocused on two franchises. The first is the largest registry-issued U.S. agricultural soil-carbon program, operated by Indigo Carbon PBC. It has issued roughly 2.1 million verified credits and is anchored by a 12-year, 2.85-million-tonne Microsoft offtake. The second is endophyte-based biologicals sold under the biotrinsic® brand with the CLIPS™ applicator, which was carved out in August 2026 as ENAI. Today Indigo is effectively a soil-carbon and sustainability-solutions company with a biologicals affiliate. --- ### Company's own description Indigo describes itself in its 2024–2025 boilerplate as a leader and trusted partner in sustainable agriculture and biological solutions. It says it was established in 2013 and operates in 15 countries. Its stated aim is to turn sustainable on-farm practices into value for farmers, agribusinesses, and corporations (Indigo/GROWMARK release, 12 Nov 2024). An earlier corporate summary listed three core offerings: Carbon, Market+, and biotrinsic. It framed them as integrated across the supply chain and as improving farmer profitability, environmental sustainability, and consumer health (Pubrio company profile, sourced from company LinkedIn). In 2026 releases, Indigo describes itself as among the largest and most mature soil-carbon programs and the only registry-issued agricultural soil-carbon credit program delivering repeated megaton-scale issuances (PR Newswire, 25 Feb 2026). ### Independent characterization As of October 2026, Indigo Ag is best understood as a soil-carbon project developer and environmental-attribute marketplace. It is attached to a legacy agricultural biologicals business that has just been separated into a standalone company, ENAI. The business works as follows. 1. **Carbon (Indigo Carbon PBC / Carbon by Indigo).** Indigo recruits U.S. row-crop farmers to adopt regenerative practices: cover crops, diversified rotations, reduced tillage, and improved nitrogen timing. It measures outcomes using soil sampling, remote sensing, and biogeochemical modeling (DayCent). It then has the results verified by a third party and issued as credits by the Climate Action Reserve (CAR) under the Soil Enrichment Protocol. Finally, it sells the credits to corporate buyers. Farmers are paid on outcomes; a third-party product listing states that 75% of the credit purchase price is returned to farmers. Indigo's revenue is the retained share of credit sales, plus fees for Scope 3 "insetting" programs and MRV services. 2. **Sustainability Solutions / Source / Market+.** These are supply-chain programs for food, beverage, biofuel, and fibre companies. Indigo measures field-level carbon intensity and verifies practice change so that buyers can claim Scope 3 reductions or capture value from clean-fuel tax credits. An example is the Red Trail Energy collaboration on low-CI ethanol feedstock. 3. **Biologicals (biotrinsic® + CLIPS™; transferring to ENAI).** These are microbial seed and foliar treatments: biostimulants, biofungicides, and bionematicides. They are sold through ag retailers, cooperatives such as GROWMARK, and distributors in the Americas, Türkiye, and elsewhere. CLIPS is a hands-free powder applicator that sits in the seed box and makes adoption easier. ### Revenue model mix (characterization; not disclosed quantitatively) | Revenue stream | Model type | Notes | |---|---|---| | Carbon credit sales | Product / commodity-like sales of environmental attributes; multi-year offtakes | Includes Microsoft (2024, 2025, and a 12-year 2026 offtake) and Catona Climate (reservation of 250k credits) | | Scope 3 / supply-chain programs | Service and program fees, premiums passed through to farmers | Market+, Source, biofuel CI programs | | MRV / dMRV services | Service / licensing | Field-level carbon-intensity calculation for partners | | Biological products | Product sales (consumables), with device enablement | biotrinsic; moving to ENAI from Aug 2026 | | CLIPS device | Product / licensing | GROWMARK described licensing of CLIPS (Nov 2024) | | Legacy grain marketplace & transport | Transaction / marketplace fees | Exited or deprioritized after 2021–2023 (see Section 3) | ### Value-chain position, customers, end-markets Indigo sits at the farm-gate interface. Upstream, it supplies inputs (biologicals) to growers and retailers. Downstream, it aggregates and certifies environmental outcomes from those growers for corporate buyers. It serves three customer groups: **growers:** (U.S. corn, soy, wheat, cotton, and other row crops; the carbon program spans 28 states and more than 8 million enrolled acres); **agribusiness channel partners:** (retail cooperatives, seed companies, distributors); **corporate buyers:** (tech companies, financial institutions, CPG/food, apparel, and biofuel producers). The main end-markets are the voluntary carbon market (VCM), corporate Scope 3 programs, U.S. clean-fuel incentive markets (45Z), and the global agricultural biologicals market.

RevenueN/A
Employees1,500
Market Cap$0.2B
Founded2013
MA, US
Indiana

Indiana Resources Limited

Premium
Information Technology

Indiana Resources is a Perth-headquartered junior explorer. Its only operating asset is the 100%-owned, royalty-free Gawler Craton Project in South Australia. The project covers about 5,000–5,713 km² between the Tunkillia gold deposit and the historic Tarcoola gold mine, and is prospective for gold, base metals, rare earths and heavy minerals. The flagship target is the Minos gold prospect. What sets Indiana apart from other juniors is its balance sheet. Between July 2024 and March 2025, the company and its co-claimants collected a US$90 million settlement from the United Republic of Tanzania over the 2018 expropriation of the Ntaka Hill nickel project. Indiana then returned two 5-cent distributions to shareholders, and still held about A$31 million in consolidated cash in March 2026. As a result, the market capitalisation (~A$14m) sits well below reported cash. That gap reflects three things: part of the cash is ring-fenced pending a shareholder arbitration with Loricatus; the company is between CEOs; and a strategic review of its South Australian assets is under way. --- **What the company does.** Indiana Resources is a pre-revenue mineral exploration company. It holds exploration licences in the Central Gawler Craton of South Australia and funds drilling, geochemistry and geophysics to discover economic deposits of gold, base metals, rare earth elements (REE) and heavy minerals (titanium). It has no mining operations, no product sales and no customers in the conventional sense. **Legacy asset monetisation.** Through UK and Tanzanian subsidiaries, Indiana held the majority interest in the Ntaka Hill nickel sulphide project in southern Tanzania. Tanzania cancelled the retention licences in January 2018 under its 2017 mining law reforms. The claimant group comprised Nachingwea UK Limited (NUKL), Ntaka Nickel Holdings Limited (NNHL) and Nachingwea Nickel Limited (NNL). It brought ICSID Case No. ARB/20/38 and obtained an award in July 2023 of more than US$109.5 million including accrued interest. In July 2024 the claimants settled with Tanzania for US$90 million, which equals 82.5% of the award, paid in three instalments; the final instalment was received in March/April 2025. These proceeds produced Indiana's FY2025 accounting profit of about A$97 million and funded its two capital distributions. **Business model.** The business model follows the standard junior-explorer path. The company spends equity or legacy cash on exploration to create value through discovery. It then monetises that value through resource definition, joint venture, farm-out, asset sale or corporate transaction, or less commonly through development. In 2024–2026 Indiana's model was unusual because its cash came from a sovereign settlement rather than equity raisings. **Revenue model mix.** **Value-chain position.** The company sits at the earliest, highest-risk end of the mining value chain: greenfield and brownfield exploration. It has no defined JORC Mineral Resource in South Australia (none was identified in the sources reviewed). **Customer types / end-markets.** There are no current customers. The eventual end-markets for any discovery would be gold (bullion and refiners), base metals concentrate buyers, REE and critical-minerals offtakers, and titanium feedstock markets. **Company's own description (paraphrased from 2026 ASX releases).** Indiana describes itself as an explorer advancing a portfolio of critical minerals, rare earths, gold and base metals tenements in the Central Gawler Craton Province of South Australia. It emphasises the ground's location between Tunkillia (a 1.7 Moz gold resource held by a third party) and the historic Tarcoola gold mine. The website brands the company as an advanced South Australian gold explorer and stresses that the package is 100%-owned, royalty-free, in a Tier-1 jurisdiction and close to rail and road infrastructure. **Independent characterisation.** In economic substance, Indiana in late 2026 is a cash-backed exploration shell with optionality on three things. The first is the South Australian ground. The second is a pending ACICA arbitration over how NNHL's share of settlement funds is split with the 18% minority holder, Loricatus. The third is a residual, contingent claim against Tanzania: US$36.9m of unpaid award balance plus interest as at May 2025, preserved because Indiana did not discontinue the ICSID proceedings after Tanzania's revenue authority issued a tax assessment. The deep discount of market value to cash shows investor scepticism about how much cash is truly distributable, how fast it is being spent, and the direction of exploration under a leadership team in transition.

RevenueN/A
Employees16
Market CapN/A
Founded1985
West Perth, Australia
India

India Glycols Limited

Premium
Information Technology

India Glycols is a promoter-controlled Indian industrial and consumer conglomerate built around one core competence: converting agricultural feedstock (molasses and grain) into ethanol and then into higher-value outputs. Founded in 1983 and the first company globally to make ethylene oxide (EO) and mono-ethylene glycol (MEG) from renewable molasses-based ethanol (commercial since 1989), it historically ran four segments — Bio-based Specialities and Performance Chemicals (BSPC), Potable Spirits, Bio-Fuel and Ennature Biopharma — from three integrated sites at Kashipur, Gorakhpur and Dehradun. In FY26 it generated ₹9,827 Cr gross revenue, ₹4,211 Cr net revenue, ₹654 Cr EBITDA (15.5% margin) and ₹293 Cr PAT. Its "3x3" model (three ethanol sources feeding three outputs) is the strategic glue. As of 1 September 2026 the group has been split into three listed-or-to-be-listed pure plays: a green-chemicals company (IGL), an alcohol-beverage-plus-ethanol platform (IGL Spirits) and a plant-based API/nutraceutical company (Ennature Bio Pharma). --- ### What the company does Pre-demerger, IGL operated an integrated agro-to-ethanol-to-derivatives value chain. Molasses (purchased from sugar mills) and grain (rice, including Food Corporation of India allocations, and other cereals) are fermented and distilled into ethanol at Kashipur (Uttarakhand) and Gorakhpur (Uttar Pradesh). That ethanol — supplemented by domestically purchased and imported ethanol when economics favour it — is routed into three outlets: 1. **Chemicals (BSPC):** dehydration to bio-ethylene, oxidation to bio-EO, and conversion into bio-MEG/DEG/TEG, glycol ethers and acetates ("green solvents"), performance chemicals (oilfield chemicals, plasticisers, bio-based amines) and, historically, ethoxylates. Bio-EO derivatives (ethoxylates) were transferred to the Clariant IGL Specialty Chemicals JV in 2021, to which IGL now supplies EO under a long-term agreement. Industrial gases (oxygen, nitrogen, argon, CO₂) are produced from an air separation unit and the EO process CO₂ stream. Guar-based biopolymers (hydrocolloids) were also reported here. 2. **Potable Spirits:** Extra Neutral Alcohol (ENA) is bottled into branded country liquor (CL, also "IMIL") and Indian Made Foreign Liquor (IMFL), primarily for Uttar Pradesh and Uttarakhand; IGL also bottles for Bacardi under a 15-year relationship and markets Amrut brands in select North Indian markets. 3. **Bio-Fuel:** fuel-grade ethanol sold to Indian oil marketing companies (OMCs) under the national Ethanol Blended Petrol programme, plus distillers' grains (DDGS/DWGS) by-products. Reported as a separate segment from Q1 FY25 (previously within BSPC). A fourth, smaller engine — Ennature Biopharma (Dehradun) — extracts plant-based APIs (global leader in thiocolchicoside, a muscle relaxant derived from Gloriosa seeds), natural nicotine and nicotine salts, and nutraceutical ingredients using supercritical CO₂ extraction. ### Company's own description (paraphrased from FY26 investor materials) IGL describes itself as one of India's leading manufacturers across BSPC, Bio-Fuel, Potable Spirits and Ennature Biopharma; the first company in the world to produce EO/MEG via the renewable molasses route (since 1989); exporting to more than 40 countries; offering 100+ green products from three integrated facilities spread over ~360 acres; with "green" positioned as core to its identity rather than a credential (Q4 FY26 Investor Presentation, May 2026). Management additionally claims, together with the Clariant JV, to be the world's largest supplier of bio-based speciality chemicals and the only at-scale producer of bio-based EO, glycols and glycol ethers (Q1 FY27 call, Aug 2026). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Overwhelmingly product sales (manufacturing). Minor service income from job-work/bottling (Bacardi), power sales from Gorakhpur cogeneration, ENA sales; royalty-paying (not royalty-earning) brand arrangement with Amrut. No meaningful subscription or licensing revenue. | | Gross vs net revenue | Gross revenue includes state excise duty on potable spirits, which inflates the top line ~2.3x. FY26 gross ₹9,827 Cr vs net ₹4,211 Cr (Q4 FY26 presentation). Analysis should use net revenue. | | Value-chain position | Vertically integrated from fermentation through to branded consumer goods (spirits) and intermediate/speciality chemicals (B2B). Upstream feedstock (molasses, grain) is bought; IGL does not grow cane, having exited sugar via the sale of Shakumbari Sugar and Allied Industries in 2023. | | Customer types | B2B: global and Indian chemical, personal care, oil & gas, textile, automotive, packaging and pharma companies; OMCs (ethanol); the Clariant JV (EO offtake); Bacardi (bottling). B2C/B2G: state excise-regulated liquor distribution in UP/Uttarakhand/Delhi, Canteen Stores Department (CSD) and paramilitary canteens. | | End-markets | Personal care, home care/detergents, oil & gas and refineries, automotive (coolants, brake fluids), textiles (MEG, glycol ethers), paints and coatings, agrochemicals, pharma/healthcare, food & beverage, packaging (PET via MEG), mining, metal working, pulp & paper, wastewater, alcoholic beverages, transport fuel. | ### Independent characterisation IGL is best understood as an ethanol arbitrage platform with three monetisation channels of very different quality. Potable spirits is the profit engine (FY26: 32% of net revenue, 52% of segment EBIT per the company's FY26 segment-share slide), protected by state licensing and by dominance in branded country liquor in UP/Uttarakhand. Bio-Fuel is a low-margin, policy-dependent volume outlet (FY26 EBIT margin 7.8%) that keeps distilleries loaded. Chemicals is a structurally challenged commodity business (bio-MEG competes against fossil MEG produced by Reliance and Middle Eastern exporters) that management is trying to pivot toward higher-margin "New Speciality" products (bio-amines, carbon-smart ethoxylates/glycols, green solvents). Historically the market applied a conglomerate discount; the demerger is explicitly designed to remove it. The key analytical tension is that the chemicals stub left in the listed IGL is the lowest-margin and least predictable piece, while the most valuable piece (spirits) now trades separately once IGL Spirits lists.

Revenue$0.1B
Employees1,357
Market CapN/A
Founded1983
Noida, India
Income

Income Asset Management Group Limited

Premium
Information Technology

Income Asset Management Group is a micro-cap Australian fixed-income investment house. It gives wholesale and sophisticated investors, financial advisers and portfolio managers direct access to bonds and bank-syndicated loans that are normally available only to institutions. Its earnings come from three activities that reinforce each other. Primary origination through its Debt Capital Markets desk earns placement fees. Principal-based secondary trading earns trading spreads. A growing layer of recurring fees comes from custody/administration (outsourced to Perpetual Corporate Trust) and, since FY2026, a Managed Discretionary Account. Funds under administration reached about A$2.8bn at 30 June 2026 across 2,800+ wholesale client accounts. After exiting term-deposit broking and funds management, IAM is now a pure-play income-markets intermediary. Its main asset is distribution capacity into a structurally growing private-wealth fixed-income market. Its main liabilities are a thin balance sheet (A$0.7m net assets), a history of losses, and recent control failures. --- ### Company's own description (FY2026 Annual Report, paraphrased) The FY2026 Directors' Report lists the Group's principal activities as: - fixed-income investment services to wholesale investors, advisers and institutions; - origination and distribution of bonds and loans; - debt capital markets activity; - custody and administration; - managed discretionary accounts. The only significant change in the year was the sale of the deposit-broking business. In the joint Chair/MD letter, management frames IAM's purpose around a structural problem: Australian investors have been under-served in direct fixed income, lacking fair, transparent access to the instruments meant to form a portfolio's defensive core. Management describes the model as a flywheel. Origination creates product, distribution creates demand, and the platform anchors the client relationship. The letter also frames trust and conduct as "the product itself", and presents tighter regulation of fees and valuations as a competitive advantage for a model built on direct access and full disclosure. The FY2025 results announcement adds that IAM serves wholesale investors seeking direct investment in bonds or loans. It also helps companies raise debt from Australian debt capital markets. It reports to ASX, AUSTRAC and ASIC, and owns Trustees Australia Limited, an ASIC-authorised Responsible Entity. ### Business model and revenue model | Revenue line (A$m) | FY2025 | FY2026 | |---|---|---| | Net trading income (principal bond/loan trading) | 8.54 | 9.94 | | Placement fees (primary bonds and syndicated loans) | 6.40 | 6.02 | | Service fees (custody/administration, RE services; recognised over time) | 0.80 | 1.40 | | Brokerage and commissions | 1.19 | 0.55 | | Other income (interest, insurance recovery, disposal gains) | 0.22 | 2.32 | | Total revenue and operational income | 17.15 | 20.24 | IAM is a service and principal-intermediation business. It has no product, subscription or licensing revenue in the software sense. FY2026 revenue mix (FY2026 AR Note 3): **Characterisation of each line:** - **Transactional and market-linked (about 82% of operating revenue in FY2026).** Trading income is recognised on trade date when IAM, acting as principal, buys from or sells to clients and the market. Placement fees are earned on trade date for arranging investor participation in new bond issues and syndicated loans, net of rebates and underwriting fees. **Recurring (about 8% of operating revenue):** Service fees are recognised over time. They grew 75% in FY2026 after IAM introduced custody/administration fees following the transition to Perpetual Corporate Trust (PCT). The MDA, which charges 0.5% p.a. management fee per the Q4 FY2026 report, adds a second recurring stream from a very small base (about A$23m FUM at 30 June 2026). **Non-recurring:** FY2026 other income includes a A$2.05m insurance recovery for fraud losses and a A$0.155m gain on disposal of the term-deposit business. ### Value-chain position IAM sits between three groups: 1. **Issuers and borrowers.** These include corporates, banks issuing Tier 2/senior paper, and syndicated-loan borrowers via arranging banks. IAM acts as DCM arranger or co-manager, or as a syndicate participant. 2. **End-investors.** These are wholesale/sophisticated individuals, family offices, advisers and small institutions. IAM is their dealer, distributor and (through PCT) custody/administration gateway. 3. **Infrastructure providers.** These include PCT (custody/administration, and acquirer of the TD business) and the major banks that structure and underwrite syndicated loans. The FY2025 results statement identifies distribution of bank-syndicated loans as a key differentiator. These loans are structured by lending banks on lender-friendly terms, and IAM's investors rank equally with the underwriting banks if credit stress occurs. ### Customer types and end-markets - Wholesale/sophisticated individual investors and SMSFs meeting wholesale tests: 2,640 clients at FY2025, more than 2,800 accounts at FY2026. - Financial advisers and advisory groups. Management expects MDA demand to come mainly from this channel. - Portfolio managers and small institutions. - Corporate and financial-institution issuers. Examples cited in the November 2025 AGM materials include syndicated loans to Foxtel (more than A$30m of senior secured loans maturing April 2030) and a A$175m bid into a Westpac 20-year Tier 2 issue in early November 2025. - End-markets: Australian investment-grade and sub-investment-grade corporate bonds, financial-institution capital securities, bank-syndicated loans, asset-backed and residential mortgage-backed securities (aggregator profile). Formerly also term deposits and at-call cash (divested). ### Independent characterisation IAM is effectively a small boutique fixed-income dealer and distributor with an embryonic wealth-platform layer. Its economics behave like a broker-dealer. Revenue tracks primary issuance volumes, secondary turnover and credit-spread conditions. Q3 FY2026 showed this sensitivity: revenue fell to about A$2.9m from A$5.35m in Q1 amid seasonal quietness and geopolitical disruption. The cost base is mostly people (employment expenses A$10.7m in FY2026, about 59% of total expenses before the fraud line). Profitability therefore depends on scaling turnover over a largely fixed team. The strategic shift is to turn the A$2.8bn FUA base into recurring, AUM-style revenue through custody fees, the MDA and a planned loan-administration fee. Doing this would lower earnings volatility and justify a higher valuation multiple. On FY2026 numbers, however, recurring revenue covers well under 10% of the cost base.

Revenue$0.0B
Employees30
Market CapN/A
Founded1986
Sydney, Australia
Incannex

Incannex Healthcare Limited

Premium
Information Technology

Incannex Healthcare is a micro-cap, clinical-stage biopharmaceutical company that is Australian in origin and now U.S.-domiciled. It develops oral fixed-dose combination drugs and psychedelic-assisted therapies for chronic conditions with poor existing treatments. Its strategy depends on IHL-42X, a once-nightly combination of dronabinol (synthetic THC) and acetazolamide for obstructive sleep apnea (OSA). IHL-42X showed statistically significant AHI reductions in the Phase 2 portion of RePOSA and holds FDA Fast Track designation. It is now in DReAMzz, a nine-arm dose-confirmation study expected to finish in mid-2027. The second asset is PSX-001, synthetic psilocybin with structured psychotherapy for generalized anxiety disorder (GAD). PSX-001 met its primary endpoint in the Australian PsiGAD1 Phase 2 trial, and the company is redesigning its next study. The company has no product revenue. As of 30 June 2026 it held USD 67.7 M of cash against a market capitalization near USD 40 M, which implies a negative enterprise value. It carries heavy dilution history, governance concerns, and an emerging oral-OSA competitor, Apnimed's AD109, which has a PDUFA date of 28 Feb 2027. --- ### Company's own description (paraphrased from 10-K FY2026) In its FY2026 Form 10-K, Incannex describes itself as a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. The development priority is IHL-42X for OSA. The company is also deciding the next clinical plan for PSX-001 in GAD and whether to develop IHL-675A further in inflammatory conditions. It states that its three lead programs were created internally and prioritized for their potential to offer new therapeutic approaches. The stated strategy has four pillars: - advance lead candidates through pivotal and registrational programs toward FDA NDAs; - pursue expedited FDA pathways (Fast Track, Breakthrough, priority review, accelerated approval) and the 505(b)(2) route; - maintain a global IP estate; - retain flexibility to partner or license assets to maximize pipeline value. After U.S. approval, it intends to expand to the EU, UK, Japan, Australia and Canada. ### Business model | Dimension | Characterization | |---|---| | Stage | Clinical-stage; no approved products; no product revenue | | Revenue model (current) | Effectively nil. FY2025 revenue was USD 86 K from clinic services (Clarion Clinics model psychedelic-therapy clinic). FY2026 revenue was USD 0 (10-K FY2026). | | Revenue mix (product / service / subscription / licensing) | 0% / ~100% of trivial historical revenue from clinic services / 0% / 0% | | Intended future model | Branded prescription pharmaceuticals (NDA route, largely 505(b)(2) for cannabinoid combinations), potentially commercialized directly in the U.S. or via partners/licensees; psychedelic-assisted therapy delivered through specialist clinics (JV with Mind Medicine Australia) | | Value-chain position | Asset originator and developer. Outsources manufacturing (Procaps for IHL-42X/IHL-675A; Ardena US, formerly Catalent Pharma Solutions, for PSX-001 cGMP), clinical execution (CROs; 14 U.S. sites for DReAMzz) and packaging/labeling (U.S. secondary packaging vendor). | | Non-dilutive funding | Australian R&D Tax Incentive (48.5% refundable offset for eligible spend for companies with turnover < A$20 M): USD 1.76 M benefit recognized FY2025 and USD 4.66 M FY2026; A$11.2 M+ cash received in calendar 2026 | | Customer types (prospective) | Sleep physicians, pulmonologists, primary care (OSA); psychiatrists and specialist clinics (GAD); rheumatologists (RA); payers/PBMs in the U.S. | | End-markets | OSA (sleep-disordered breathing); anxiety disorders (GAD); inflammatory/autoimmune disease (RA, potentially IBD, COPD, asthma) | ### Independent characterization Incannex is best understood as a single-asset optionality vehicle (IHL-42X) with one secondary, partially de-risked psychiatric asset (PSX-001). It has a deep but largely dormant "secondary asset" shelf (25 additional candidates, mostly inherited from the 2022 APIRx acquisition). The scientific thesis is to combine two approved, off-patent molecules with distinct mechanisms at lower doses, aiming for synergy and tolerability. The regulatory thesis is the 505(b)(2) pathway, which leverages existing safety data. FDA's combination rule requires that each component contribute to efficacy. That is why the originally designed RePOSA Phase 3 was factorial (IHL-42X vs. each component vs. placebo), and why dose-ratio optimization (DReAMzz) now precedes Phase 3. The model is capital-light (12 employees, outsourced CMC/clinical), and Australian tax incentives subsidize it. Its persistent constraint is a small market capitalization relative to Phase 3 costs, which has historically forced highly dilutive financings: pre-split shares rose from 17.6 M (Aug 2024) to ~358 M (Feb 2026). The balance-sheet reset in FY2026 (USD 78.7 M of share-issuance proceeds) temporarily removed near-term financing pressure. It does not fund a full Phase 3 OSA program, which in the original RePOSA design targeted 560+ patients globally.

RevenueN/A
Employees12
Market Cap$0.0B
Founded2001
Melbourne, Australia
Imugene

Imugene Limited

Premium
Information Technology

Imugene Limited is a Sydney-headquartered, ASX-listed clinical-stage cell therapy company that, after a decade as a multi-platform immuno-oncology developer, has collapsed its pipeline onto a single asset: azercabtagene zapreleucel (azer-cel), an off-the-shelf allogeneic CD19 CAR T therapy in-licensed from Precision BioSciences in August 2023. Azer-cel is in a three-cohort Phase 1b basket study across ten US and five Australian sites, targeting CAR T-relapsed diffuse large B-cell lymphoma (DLBCL), CAR T-naïve B-cell malignancies, and patients progressing on BTK inhibitors. The asset carries three FDA Fast Track Designations (DLBCL post-CAR T; CLL/SLL; MZL). The company's investment case rests on high early response rates (82% ORR in CAR T-relapsed DLBCL; 79% in the CAR T-naïve cohort at ASCO 2026) set against acute balance-sheet fragility: A$2.6m cash at 30 June 2026, an A$105.3m FY2026 loss, a 34:1 consolidation, repeated deeply discounted raises, and an interim leadership structure after the CEO's July 2026 resignation. --- **Company's own description (FY2026 Annual Report).** Imugene describes itself as a clinical-stage cell therapy company developing an off-the-shelf (allogeneic) CAR T therapy for blood cancers, stating that its lead and sole clinical program is azer-cel, a donor-derived CD19 CAR T that can be ready to administer within days rather than the three to six weeks required to manufacture conventional autologous CAR T from a patient's own cells. Its stated mission is to develop transformative cancer medicines to improve patients' lives, under the values of innovation, patient-centricity, relationships, integrity and excellence. The Directors' Report describes the Group as "an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers." **Independent characterisation.** Imugene is best understood today as a capital-markets-funded, virtual development company holding an in-licensed late-Phase 1 cell therapy asset. It owns no manufacturing (its North Carolina cGMP facility was sold to Kincell Bio in April 2024, with Kincell now the contract manufacturer), runs a 14-person organisation, and outsources clinical execution to academic and community trial sites in the US and Australia. Value creation is entirely contingent on (i) generating registration-enabling clinical data, (ii) securing an FDA-agreed pivotal path (an FDA meeting in December 2025 reportedly validated dosing, population, endpoints and manufacturing readiness), and (iii) either licensing/partnering azer-cel with a large biopharma company or financing a pivotal study itself. The July 2026 placement included an unnamed international commercial-stage biopharmaceutical company subscribing ~14% of the placement, which management frames as a signal of strategic interest. **Business model and revenue model.** **Operational footprint of the business model.** The company's own accounts show the scale of de-risking via cost reduction: FY2026 payments to suppliers and employees fell A$35.7m (40%) to A$53.7m; employee benefits costs fell A$8.2m (45%); staff cash costs fell from A$20.5m to A$11.2m; executive headcount fell from 24 to 14 (FY2026 Annual Report, pp. 19–20, 32–33).

RevenueN/A
Employees14
Market CapN/A
Founded2001
Sydney, Australia
Imperium

Imperium Technology Group Limited

Premium
Information Technology

Imperium Technology Group is a Hong Kong-headquartered micro-cap holding company. Over 2018 to 2021 it pivoted from stainless-steel kitchen and bathroom furnishings into a portfolio of digital-entertainment and blockchain-adjacent businesses. Its economic core today is the NOVA ("NV") esports club, which competes in Tencent- and Riot-sanctioned Chinese leagues and generated about 61% of FY2026 revenue. Two activities sit alongside it. The first is a licensed online-game publishing operation dependent on a decade-old wuxia MMO, *Jiuyin Zhenjing*. The second is a shrinking Filecoin storage-mining and machine-leasing operation that is being repositioned towards AI services (the TokenTrend app and an AI-API aggregation layer). The group has never been profitable since the pivot. It carries a capital deficiency of HK$129.4m and relies on HK$183m of carrying-value loans from entities linked to its former controlling shareholder, Mr. Cheng Ting Kong. Its latest accounts received an auditor's disclaimer. The investment case is a speculative, financing-dependent turnaround rather than an operating franchise. --- ### Company's own description (paraphrased from AR FY2026 and RA FY2026) Management says that since 2018 the group has rebuilt itself around three pillars: online game publishing, cloud computing-related services, and esports. It presents innovation, cutting-edge technology and an understanding of consumer behaviour as the basis of the strategy. The FY2026 annual report restates the principal activities as: - marketing and operating mobile and computer games, and selling NFTs and other digital tokens; - providing cloud computing and data storage solutions; - taking part in esports competitions, streaming, marketing events and merchandise sales. Property investment and a residual household-products and money-lending business are reported together as "other" activities. The Future Prospects section points the strategy towards applying AI, blockchain and Web3 to the existing businesses. Management also says it will stay cautious because these markets change quickly. ### Independent characterisation On the numbers, Imperium is best understood as an esports club operator with attached legacy and option-value businesses, funded by related-party debt and repeated equity issuance. **Esports (HK$32.6m, 60.9% of FY2026 revenue).** NOVA is a mid-tier Chinese esports organisation. About 73% of its revenue comes from rewards distributed by league organisers for marketing activity, rather than from prize money (6.8%). This makes the segment a quasi-franchise revenue-share business that depends on organiser economics, chiefly Tencent's Peacekeeper Elite League (PEL) and Riot/Tencent's Valorant China ecosystem. Player transfer fees (14.7%) are lumpy. **Online games (HK$17.1m, 31.9%).** This is a licence-based publisher, not a developer. Roughly 70% of segment revenue comes from one title, *Jiuyin Zhenjing* (Age of Wushu), published in Southeast Asia for more than ten years. The second title, *Champion Horse Racing* (since 2019), contributes about HK$1.5m. The group spent heavily on in-house metaverse IP (Metasens/Holosens). It wrote off all related intangibles in 2023 and scaled Holosens down in FY2026. **Cloud computing and data storage (HK$1.7m, 3.1%).** This is a Filecoin storage-mining operation. At 31 March 2026, 34.2 PiB of capacity was leased to customers and 15.0 PiB was mined on own account. Revenue is falling structurally as network output per unit of storage declines and the FIL price weakens. A Bitcoin-mining venture launched in early 2025 was shut in mid-2025. The segment now also houses TokenTrend (a crypto-market data and AI-assistant app, not yet monetised) and a 30% associate stake in VividVerse Capital (AI plus blockchain real-world-asset and IP applications). **Property investment (HK$1.8m, 3.4%).** This is rental income from investment properties carried at HK$23.2m. Management's contingency plans identify these properties as being in Malaysia. **Others (HK$0.4m, 0.7%).** These are the vestigial household-products business (no FY2026 sales) and a money-lending book that has made no new loans since 2020. ### Revenue model mix (FY2026, RA FY2026 Note 4) | Revenue type | HK$'000 | % of total | |---|---|---| | Esports: organiser marketing rewards, prize money, transfers, merchandise (service/contract revenue) | 32619 | 60.9 | | Online game publishing (in-game purchases, net platform revenue; licensing-based) | 17086 | 31.9 | | Cloud computing and data storage: mining revenue (HKFRS 15) | 1355 | 2.5 | | Cloud computing: machine rental income | 321 | 0.6 | | Rental income from investment properties | 1798 | 3.4 | | Interest income from money lending | 400 | 0.7 | | Total | 53579 | 100.0 | Product sales (physical goods) were effectively zero in FY2026, against HK$1.9m in FY2024 and HK$18.3m in FY2023. Subscription revenue does not yet exist. TokenTrend subscriptions were targeted for late 2026, and the AI-API launch has been pushed to Q1 2027 (announcement, 30 September 2026). ### Value-chain position, customers and end-markets **Esports:** The group sits downstream of game IP owners and league organisers, who are both its key customers and the gatekeepers of its revenue. "Customer A" in esports accounted for HK$15.8m (30.7% of revenue) in FY2024 (RA FY2024 Note 4). In FY2026 the largest customer was 17.6% of sales and the top five were 56.8% (AR FY2026). **Games:** The group is a regional publisher and localiser sitting between Chinese developers and Southeast Asian players. Distribution runs through app stores, web portals and the group's own websites. End customers are retail gamers in Southeast Asia and, for *Champion Horse Racing*, worldwide. **Cloud/Filecoin:** The group is an infrastructure owner-operator leasing storage-mining capacity to retail and corporate crypto participants and mining for itself. **Supplier concentration is high:** The largest supplier was 37.2% of purchases and the top five were 65.1% in FY2026. The likely candidates are game licensors and software developers, but the filing does not name them. **Geographic end-markets (FY2024):** The PRC excluding Hong Kong was 60.6% of revenue, Hong Kong 24.8%, and East and Southeast Asia 14.6%.

Revenue$0.0B
Employees115
Market CapN/A
Founded1999
P.O. Box, Cayman Islands
ImpediMed

ImpediMed Limited

Premium
Information Technology

ImpediMed is a small-cap Australian medical-technology company that commercialises bioimpedance spectroscopy (BIS) through its SOZO® Digital Health Platform — a hand-and-foot-plate measurement device paired with cloud software (MySOZO) that delivers non-invasive fluid and tissue-composition metrics in roughly 30 seconds. Its anchor indication is the early detection of breast-cancer-related lymphoedema (BCRL) via the proprietary L-Dex® score, for which ImpediMed describes itself as the only company offering FDA-cleared BIS technology. Commercial traction rests on three pillars built over 2023–2026: inclusion of BIS in NCCN Survivorship Guidelines and NAPBC breast-centre standards, a dedicated CPT code (93702), and US payer coverage that reached 95.0% of covered lives (331M) by June 2026. Around 90% of revenue is US-derived. The company is now extending SOZO into heart failure (HF-Dex) and GLP-1-era body composition, but remains loss-making (FY2026 net loss A$24.9M on A$14.6M revenue), heavily diluted, and dependent on further capital. --- ### What the company does ImpediMed designs, manufactures (via outsourced/contract arrangements; manufacturer of record on FDA filings is ImpediMed Limited, Australia) and sells medical devices that apply bioimpedance spectroscopy — passing a low-level electrical current through the body across a spectrum of frequencies — to estimate extracellular fluid, intracellular fluid, total body water, and body-composition parameters (fat mass, fat-free mass, skeletal muscle mass). The flagship SOZO system (and successor SOZO Pro) is used under physician direction for: **Lymphoedema assessment:** (L-Dex®), primarily in breast-cancer survivorship programmes — the "SOZO Core Business"; **Heart failure fluid monitoring:** (HF-Dex), including patients with cardiac implantable devices (SOZO Pro clearance, Oct 2023); - **Protein-calorie malnutrition / body composition**, including the newly targeted GLP-1 weight-management and sarcopenia use-cases. ### Company's own description (paraphrased from FY2026 H1 and FY2026 Q4 releases) ImpediMed describes itself as a medical technology company using BIS to generate data that maximise patient health, producing the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked and ARTG-listed for multiple indications (lymphoedema, heart failure, protein-calorie malnutrition), and sold in select markets globally. It positions SOZO as part of the patient journey from active cancer treatment through long-term survivorship monitoring, and frames the large cancer-related lymphoedema market as an opportunity for growth through its SaaS subscription-based business (Appendix 4D H1 FY26, 26 Feb 2026; Q4 FY26 Appendix 4C, 28 Jul 2026). ### Business and revenue model **Contract structure:** Customers (predominantly US hospitals, cancer centres and integrated delivery networks) sign multi-year agreements — typically three years — that include consideration for the SOZO unit plus licence/usage fees for the contract duration (definition of Total Contracted Value, Appendix 4D H1 FY26). **Revenue recognition:** Since Q2 FY24 the company reports all revenue associated with each contract as revenue from contracts with customers rather than separating "device" and "recurring subscription" revenue (Q2 FY24 Quarterly Report). Recurring usage fees are dominant: in H1 FY26, SOZO recurring usage fees were A$7.2M of A$7.5M total revenue (≈96%), up 26% YoY (Appendix 4D H1 FY26). **Key KPIs:** Annual Recurring Revenue (ARR — next-12-month revenue expected from existing contracts, assuming installation and no churn), Total Contract Value (TCV — new and renewed contracts), units sold, covered lives, churn and renewal pricing. **Revenue mix (by type):** Predominantly SaaS/recurring licence (≈96% in H1 FY26); small device/distributor sales (e.g., the Australian distributor's 38-unit order in Q2 FY26); legacy devices and consumables (L-Dex U400 / SFB7-era products) now immaterial; clinical-trial revenue (AstraZeneca programme) ceased in FY24. **Gross margin:** High software-like gross margins — 86% (FY2023), 87% (FY2024), 86% (FY2025), 87% (FY2026) (FY24 results release; FY26 results summary). ### Value-chain position ImpediMed sits at the device-plus-software layer of the point-of-care diagnostics value chain: it owns IP, algorithms (L-Dex, HF-Dex scoring), regulatory clearances and the cloud platform, while outsourcing much of the hardware supply chain (the company referenced long-lead electronic component payments in Q1/Q2 FY26 Appendix 4C commentary). It sells direct in the US through a field sales force and via distributors elsewhere (e.g., Australia). ### Customer types and end markets | Customer type | Evidence (source) | |---|---| | US cancer centres / breast centres | 172 of the top 500 US cancer centres are customers, including 24 of 33 NCCN centres (H1 FY26 investor materials as reported by StockWire X, Feb 2026) | | Integrated delivery networks (IDNs) | 17 of the 20 top IDNs by patient revenue are customers (same source); SOZO deployed across all 15 of the top 15 US IDNs offering lifestyle medicine/primary care programmes (Appendix 4D H1 FY26) | | Top US hospitals | SOZO in 18 of the top 25 US hospitals; ~600 devices deployed in the US at H1 FY26 and 642 installed at Q4 FY26 | | Heart failure programmes | First Heart Health sale to an IDN in Texas (H1 FY26) | | Weight-loss, lifestyle-medicine and wellness clinics | Body-composition launch, 3.5 dedicated sales reps, 3,000+ leads (H1 FY26) | | International distributors | Australian distributor ordered 38 units in Q2 FY26 (Q2 FY26 Appendix 4C) | | Pharma clinical trials (historic) | AstraZeneca clinical-trial programme; revenue fell from A$2.0M (FY23) to A$0.1M (FY24) (FY24 results release) | ### Independent characterisation ImpediMed is effectively a single-product, single-geography (US) oncology-survivorship SaaS business with ~A$14–15M of recurring-heavy revenue, an installed base of ~640 US units, and a structurally unprofitable cost base (FY2026 operating cash burn A$17.9M). Its moat is regulatory and guideline-based rather than technological scale: it holds the only FDA-cleared BIS lymphoedema indication, has guideline endorsement (NCCN, NAPBC), a dedicated CPT code, and near-universal US payer coverage. However, conversion of that clinical/reimbursement position into unit growth has repeatedly lagged expectations (Canaccord, Feb 2026, noted the anticipated sales acceleration had yet to arrive). The diversification into heart failure and GLP-1 body composition is strategically logical (same hardware, existing hospital contracts and IT/security approvals) but is at a very early stage, while the balance sheet is fragile (going-concern doubt in FY2026 accounts, per Capital IQ headline).

Revenue$0.0B
Employees76
Market CapN/A
Founded1999
Pinkenba, Australia
Immutep

Immutep Ltd.

Premium
Information Technology

Immutep is a clinical-stage Australian–French biotechnology company whose entire scientific franchise is built around Lymphocyte Activation Gene-3 (LAG-3), a protein discovered by its Chief Scientific Officer, Prof. Frédéric Triebel. Its portfolio spans the full LAG-3 pharmacology spectrum: eftilagimod alfa (efti), a soluble LAG-3 fusion protein that acts as an MHC Class II agonist to activate antigen-presenting cells in oncology; IMP761, a first-in-class LAG-3 agonist antibody designed to dampen self-reactive T cells in autoimmune disease; and out-licensed antagonist assets. FY2026 was a defining reversal: the registrational TACTI-004 Phase III in first-line NSCLC was discontinued for futility in March 2026, the share price collapsed by roughly 85–90%, and a root-cause analysis subsequently pointed to manufacturing-scale differences (200L vs 2,000L product). The company now trades near its cash balance and has narrowed efti to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma, while advancing IMP761. --- ### What the company does Immutep discovers and develops immunotherapies that modulate the LAG-3 / MHC Class II axis. It has no marketed products, no commercial infrastructure and no product revenue. Its economic model is that of a platform-IP biotech: it funds early and mid-stage clinical development itself (often in combination with partners' approved drugs supplied free of charge, e.g., MSD's KEYTRUDA), and monetises assets through regional licences, milestone payments and royalties, while retaining rights in major markets. ### Company's own description (paraphrased from FY2026 disclosures) Immutep describes itself as a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, with a diversified portfolio that harnesses LAG-3's ability either to stimulate the immune system (oncology) or to suppress it (autoimmunity). Through early 2026 the company styled itself a "late-stage immunotherapy company"; following the TACTI-004 discontinuation its quarterly reports from April 2026 onward reverted to "clinical-stage biotechnology company" — a telling change in self-characterisation. ### Independent characterisation Immutep is best understood as a single-target (LAG-3), two-asset (efti, IMP761) company with an unusually mature clinical dataset for efti (≈600 patients across five earlier studies, per ASCO 2026 pooled analysis) that is now clouded by a failed Phase III whose most plausible explanation, per the company, is a change in drug product. The investment and strategic question has shifted from "will efti be approved in NSCLC?" to "is 200L-scale efti a different, better-performing molecule than 2,000L-scale efti — and can the company afford to prove it?" ### Revenue model mix | Revenue type | Description | FY2026 relevance | |---|---|---| | Product sales | None | 0% | | Licensing — upfront & milestones | Dr. Reddy's (efti, emerging markets), EOC Pharma (efti, Greater China), historically Novartis (ieramilimab) and GSK (GSK2831781) | Dominant FY2026 driver (Dr. Reddy's upfront; US$10M of US$20M later repaid) | | Royalties | Potential double-digit royalties from Dr. Reddy's territories; none currently earned | 0% | | Grant income | Primarily French research tax credit (Crédit d'Impôt Recherche) and Australian R&D incentives (classification varies) | Material contributor to "other income" | | Interest income | Return on cash and term deposits | A$5.29M in FY2025 (S&P Global); declining with cash balance | ### Value-chain position Immutep occupies the discovery-to-clinical-proof-of-concept segment. Manufacturing is outsourced to contract development and manufacturing organisations (the specific CMOs for 200L and 2,000L campaigns are not named in the 2026 sources reviewed); Immutep retains global manufacturing rights for efti and is obligated to supply licensees (Dr. Reddy's). Clinical trials are run via CROs and investigator-initiated trial (IIT) networks. ### Customer types and end-markets Customers today are licensing partners (pharma companies), not patients or payers. Therapeutic end-markets targeted: head and neck squamous cell carcinoma (HNSCC, specifically PD-L1 CPS<1), soft tissue sarcoma (neoadjuvant), non-small cell lung cancer (investigator-led INSIGHT-003), metastatic breast cancer (AIPAC-003 follow-up), and autoimmune diseases (IMP761 — company has cited type 1 diabetes, rheumatoid arthritis and psoriasis as potential applications, per CEO interview with Finance News Network, May 2026).

Revenue$0.0B
Employees51
Market CapN/A
Founded1987
Sydney, Australia
Immuron

Immuron Limited

Premium
Information Technology

Immuron is an Australian commercial- and clinical-stage biopharmaceutical micro-cap built on a proprietary platform of orally delivered polyclonal antibodies harvested from the colostrum of dairy cows immunised against specific gut pathogens. Its economic engine today is Travelan®, an over-the-counter tablet for reducing the risk of travellers' diarrhoea, sold as a listed medicine in Australian pharmacy, a natural health product in Canada and a dietary supplement in the United States; Travelan generated essentially all of FY2026 revenue of A$7.71 million. Gross margins are attractive (64.5% in FY2026) but the business remains loss-making after sales, marketing and corporate costs. Behind the consumer franchise sit two FDA-IND-stage prescription assets — IMM-124E (travellers' diarrhoea) and IMM-529 (Clostridioides difficile infection) — which, following a February 2026 "Strategic Reset", management now intends to out-license rather than fund through Phase 3. The investment case is therefore a hybrid of a small, growing consumer-health brand and binary partnering optionality on the pipeline. --- ### Company's own description (FY2026 Form 20-F, paraphrased) In its FY2026 annual report on Form 20-F, Immuron describes itself as a commercial and clinical-stage biopharmaceutical company whose proprietary technology platform develops and commercialises a novel class of specifically targeted polyclonal antibodies aimed at significant unmet medical needs. It currently markets Travelan® and ProIBS® in Australia (both listed on the Australian Register of Therapeutic Goods — Travelan AUST L 106709; ProIBS AUST L 482225), Travelan in Canada as a licensed natural health product (NPN 80046016), and Travelan in the U.S. as a dietary supplement for digestive tract protection. Protectyn® (AUST L 231001), previously sold online and through practitioner clinics as an immune/digestive supplement, was cancelled and removed from the ARTG in June 2026. The company emphasises that its antibodies act within the gastrointestinal tract and do not enter the bloodstream, which it believes supports safety and tolerability. The 20-F's liquidity section describes a "two-pronged" value-creation approach: in the short to medium term, sell and license the Travelan OTC product; beyond that, research and clinically develop products principally for travellers' diarrhoea and C. difficile infection. ### Platform technology Pregnant dairy cows are immunised with vaccines containing antigens of human enteric pathogens. The resulting hyper-immune bovine colostrum (HBC) is rich in pathogen-specific IgG. According to the company, bovine IgG survives gastric acid and resists proteolysis, remaining active in the human GI tract where it binds bacteria, blocks colonisation and neutralises toxins. IMM-124E (the active in Travelan) is generated from cows vaccinated with outer antigens of 13 human-derived enterotoxigenic E. coli (ETEC) strains; the colostrum contains antibodies against ETEC LPS, CFA-I and flagellin. IMM-529 targets three C. difficile virulence components — Toxin B, spores and surface-layer proteins of vegetative cells — and was developed with Dr Dena Lyras' group at Monash University. ### Business model and revenue model | Revenue model element | FY2026 contribution | Comment | |---|---|---| | Product sales (OTC consumer health) | 100% of revenue from contracts with customers (A$7.71m) | Travelan 98.6%, ProIBS 1.1%, Protectyn 0.3% | | Licensing / royalties | 0% | Management intends to out-license IMM-124E and IMM-529; no deal signed as of October 2026 | | Contract research / manufacturing services | First revenue received May 2026 under the DoD/HJF Campylobacter–Shigella program (amount not separately disclosed); HJF R&D grant A$339,819 booked as other income | 20-F risk factors reference "our ability to successfully expand our contract manufacturing services" | | Subscriptions / services | None | — | | Non-operating support | Australian R&D Tax Incentive (A$782,313 audited, FY2026) and R&D grants (HJF A$339,819) recorded in other income | Material relative to revenue; proposed May 2026 reforms may end eligibility (Section 18) | ### Value-chain position Immuron is an asset-light brand owner and IP holder. It does not own farms or factories. Hyper-immune colostrum for IMM-124E is produced by Bovogen Biologicals (Australia); finished Travelan product is made by contract manufacturers including Mayne Pharma International; IMM-529 GMP process development is with Syntro Health (FY2026 20-F risk factors). Immuron controls vaccine/antigen know-how, regulatory dossiers, brand, marketing and distribution relationships. Downstream, it sells through pharmacy wholesalers and retailers in Australia (notably Chemist Warehouse/Sigma), Amazon and online channels in the U.S., and pharmacy chains in Canada (including Jean Coutu in Québec from Q3 FY2026). ### Customer types and end-markets | Customer type | End-market | Products | |---|---|---| | Pharmacy wholesalers and retail chains (Australia) | Consumer travel health; digestive health/IBS | Travelan, ProIBS | | E-commerce (Amazon U.S.) and U.S. retail | Consumer dietary supplements / travel health | Travelan | | Canadian pharmacy chains (>1,000 doors listed in FY2025; Jean Coutu, Québec, FY2026) | Natural health products / travel health | Travelan | | U.S. Department of Defense research bodies (NMRC, WRAIR via Henry M. Jackson Foundation) | Military force-health protection R&D | Bespoke HBC products for pre-clinical evaluation | | Future pharma licensees (sought) | Prescription anti-infectives (TD prophylaxis; CDI) | IMM-124E, IMM-529 | ### Independent characterisation Immuron is best understood as a sub-scale consumer-health brand company carrying a legacy biotech cost structure and listing burden (dual ASX/Nasdaq). Travelan has demonstrably scaled post-COVID — revenue rose roughly tenfold from FY2022 to FY2026 — but growth decelerated sharply to 5.9% in FY2026 as the post-pandemic travel rebound normalised and Canada's pipeline-fill comparison unwound. The prescription pipeline has been de-risked regulatorily (two INDs) but not clinically for the commercial dosing regimen in a field setting: the December 2025 military field study missed its primary endpoint, albeit with a third-party product dosed off-label. The February 2026 pivot to partnering is an explicit admission that the balance sheet cannot fund Phase 3. Value therefore depends on (a) whether Travelan can sustain double-digit growth and reach EBITDA (ex-R&D) breakeven, and (b) whether IMM-529 in particular can attract a licensee on terms that matter relative to a ~US$14 million market capitalisation.

Revenue$0.0B
Employees7
Market Cap$0.0B
Founded1994
Victoria, Australia
ImExHS

ImExHS Limited

Premium
Information Technology

IMEXHS is a Latin America-focused, cloud-native medical imaging software and radiology services company listed in Australia. Founded by Colombian radiologists and engineers in 2012, it sells a vendor-neutral, zero-footprint suite: PACS, RIS, cardiology information system, anatomical pathology LIS and universal viewer. These are now consolidated on the Aquila+ platform, which embeds proprietary "agentic" AI workflow agents. The company also owns RIMAB SAS, a Colombian outsourced radiology and teleradiology provider that runs entirely on IMEXHS software. RIMAB generates about two-thirds of group revenue and acts as a live laboratory and data source for the AI agents. With A$29.0m FY25 revenue, A$36.8m ARR at June 2026 and about 97% recurring revenue, IMEXHS is a sub-scale but recently EBITDA-positive challenger to global PACS incumbents. It competes on cost, cloud delivery, Spanish-language local support and partner-led distribution across 18 countries. Its principal exposures are Colombian healthcare-payer liquidity and customer concentration. --- ### What the company does IMEXHS operates two complementary business units, which are also its two reportable segments. 1. **IMEXHS Software.** This unit develops and sells cloud-based medical imaging software on a subscription (SaaS) basis. The product set covers: - Picture Archiving and Communications System (PACS) - Radiology Information System (RIS) - Cardiology Information System (CIS) - Anatomical Pathology Laboratory Information System (APLIS) - a universal diagnostic viewer, patient portal and results-distribution tools The company describes its solutions as completely cloud-based, vendor neutral and zero footprint, with no need for locally installed software (company boilerplate, 1H FY26 announcement). Since 2025 the flagship is Aquila+, the next-generation radiology platform. Aquila v3 remains in use and is often deployed alongside Aquila+ (2026 AGM address). By 30 June 2026 the company had 569 IMEXHS Enterprise and IMEXHS Cloud installations worldwide (1H FY26 results). 2. **Radiology Services (RIMAB SAS).** This unit provides outsourced radiology, teleradiology and outpatient-clinic imaging services, mainly in Colombia. It serves hospitals, insurers (EPS) and clinic networks. RIMAB was acquired in October 2021. It operates exclusively on IMEXHS software, and AI agents built by the software business run inside RIMAB's own operation (1H FY26 Results Presentation). ### Business model and revenue model | Revenue type | Description | Share of revenue | |---|---|---| | Subscription SaaS (software) | Monthly recurring fees for IMEXHS Cloud (standardised, multi-tenant) and IMEXHS Enterprise (larger, customised deployments). Often priced per study or volume band. | Software was about 34% of FY25 revenue (derived: A$10.0m of A$29.0m) and 30% of 1H FY26 revenue (A$4.8m of A$16.0m) | | Recurring services (radiology) | Contracted reading and reporting, on-site radiology department management and teleradiology. Billed monthly, frequently per-study volume. | About 66% of FY25 revenue (A$19.0m) and 70% of 1H FY26 revenue (A$11.2m) | | One-off / implementation | Implementation fees (for example a US$50,000 one-time fee on the Zacatecas, Mexico tender), hardware and occasional perpetual or one-off sales | Small. Recurring revenue was about 97% of total in FY25 (AGM 2026 commentary). | | Licensing via partners | Partner Programme distributors resell IMEXHS Cloud/Aquila+ | Included in software. Partners delivered 75% of software new ARR in 1H FY26. | The company's key operating metric is Annualised Recurring Revenue (ARR), defined as monthly recurring contract revenue multiplied by twelve. A further component, "contracted but not yet billing" ARR, is reported separately. This was A$2.3m for software at 30 June 2026 (1H FY26 results). ### Value chain position IMEXHS sits at the clinical-IT application layer of the diagnostic imaging value chain: **Upstream:** modality OEMs such as CT, MR and X-ray makers. Neusoft Medical is a partner (December 2021). **Downstream:** radiologists and referring clinicians. **Third-party AI:** algorithms are integrated on top. Gleamer's ChestView and Fracture Detection were embedded in the 2026 Mexico tender. Through RIMAB, IMEXHS also integrates forward into the clinical service itself. That makes it unusual among PACS vendors: it is both a software vendor and a radiology service operator. ### Customer types and end markets | Customer type | Examples disclosed | |---|---| | Public hospitals / health systems | Colombian National Police Central Hospital (contract December 2021, renewed Q4 FY24); 20 public hospitals and clinics in Zacatecas, Mexico (May 2026 tender via distributor GOBA); Subred Integrada de Servicio de Salud Sur ESE, Bogotá | | Private hospital groups / clinics | Hospital General de Medellín; Clínica del Occidente; Hospital Moncaleano; Hospital La Misericordia; Neurológico de México; CESAC IPS (Cartagena); Clínica El Carmelo (El Salvador) | | Health insurers / payers (EPS) and integrated providers | Colsubsidio; Famisanar (A$1.1m ARR, March 2023); Sanitas and Colsanitas (two radiology contracts commencing Q3 FY26, about A$2.0m combined ARR) | | Diagnostic imaging centres and outpatient networks | Diodiagnóstico (extension bringing ARR to A$490,000); DPI (Peru); Pulso Salud (Peru, A$163,000 NARR); Imágenes del Centro (Venezuela, five centres); Someditec | | Channel partners | 47 partners across 13 LATAM countries (1H FY26), mainly Colombia (15), Mexico (9) and Ecuador (6) | End markets are diagnostic imaging IT and radiology services in Latin America, mainly Colombia, Mexico, Peru, Ecuador and Central America. There is a residual presence in Spain, the US and Australia; boilerplate states 18 countries "including Colombia, the US and Australia". ### Company's own description versus independent characterisation **Company description (paraphrased from the 2026 AGM and 1H FY26 materials):** IMEXHS runs two complementary businesses with a single mission of making specialist medical imaging diagnosis more efficient and accessible. The software division builds cloud-native radiology software centred on Aquila+, now an AI-native, agentic platform. The radiology services division (RIMAB) places radiologists and reporting capacity into hospitals and runs on that software. **Independent characterisation:** Economically, IMEXHS is a Colombian radiology services business (about 66–70% of revenue, thin but improving margins) attached to a small, higher-margin regional SaaS business. The software business has about A$11.8m ARR and roughly a 30% segment EBITDA margin in FY25 (AGM 2026 summary). The investment case rests on the software unit scaling through partners and Aquila+, while RIMAB funds itself and supplies proprietary workflow data. The main structural weaknesses are: - exposure to Colombian payer liquidity - a single customer at about 33% of external FY25 revenue - low absolute scale against global incumbents - a history of equity dilution

Revenue$0.0B
Employees300
Market CapN/A
Founded2012
Colombia
Imdex

Imdex Limited

Premium
Information Technology

| Metric | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |---|---|---|---|---|---|---| | Full-time employees at 30 June | 521 | 622 | 851 | 816 | 816 | 1057 | FY23 includes 187 Devico employees. FY26 includes 194 employees integrated through acquisitions (FY22 Results Presentation; FY23 Results Announcement; FY26 Annual Report). IMDEX is a Perth-based mining-technology and earth-sciences company. It sits at the point where subsurface data is created: the drill site. Its AMC drilling fluids and REFLEX/Devico downhole sensors make it the leading global supplier of drilling optimisation products, survey instruments and core-orientation tools to more than 150 drilling contractors and more than 500 resource companies in more than 100 countries. The company's strategic thesis is to monetise that installed base. Connected sensors stream data through IMDEX HUB-IQ into an expanding software, AI and geoscience-analytics layer, the newly formed Digital Earth Knowledge unit. That unit was assembled through five acquisitions in FY26. The model is rental-heavy, patent-protected (550+ patents; more than 72% of tool revenue patent-protected) and capital-light (capex ~10–15% of revenue). It is still cyclically tied to global non-ferrous exploration budgets. FY26 was a record year: revenue of A$520m (+21%) and normalised EBITDA of A$163m at a 31% margin. Platform revenue reached 47% of the group, up from 33% in FY21. --- ### Company's own description (FY26 Annual Report) IMDEX describes itself as "a leading global mining technology and earth sciences company that enables customers to find, define and optimise the subsurface with precision, confidence and at speed." Its technologies are described as commodity-agnostic. They span drilling optimisation products, cloud-connected rock-knowledge and geophysical sensors, and real-time data and analytics, applicable across the mining lifecycle. The company frames its offer as an "Integrated Physical-to-Digital Platform" with three layers: 1. **Capture** — high-quality rock data at the source, from tools, sensors, fluids and integrated on-site services. 2. **Analyse** — turning rock data into orebody insights at scale through digital technologies such as the digital drill rig, connected fleet and EarthNET. 3. **Solve** — turning insights into decisions through decision intelligence: core logging, geophysics, and geological domaining with model-ready data. ### Business model and revenue model | Revenue stream | Nature | FY24 (A$m) | FY25 (A$m) | FY26 (A$m) | FY26 % of group | |---|---|---|---|---|---| | Platform-enabled hardware rentals | Recurring rental of connected sensors (gyros, core orientation, logging) | 163 | 176 | 227 | 44% | | Software and platform advisory | SaaS/licences (ioGAS, aiSIRIS, HUB-IQ, Datarock, EarthNET, Krux, WellCAD) and advisory | 8 | 9 | 19 | 4% | | Product sales | Mainly AMC drilling fluids, plus equipment and instrument sales | 147 | 135 | 151 | 29% | | Rentals and other, plus integrated on-site services (combined, derived residual) | Legacy/non-connected rentals; Directional Core Drilling (DCD) and IMDEX Managed Services | 127 | 111 | 123 | 24% | | Total | — | 445 | 431 | 520 | 100% | | Category | Share | |---|---| | Rental (connected and legacy) | ~55–60% | | Product sales (fluids-dominated) | ~29% | | Services (DCD, managed services) | ~9–10% | | Software and subscription | ~4% | | Licensing (separately) | n/d | IMDEX earns revenue through five mechanisms (FY26 Results Presentation, slide 14): The company also reports a two-way split from FY26 (FY26 Annual Report): **Platform:** (connectable sensors, software and platform advisory across DST and DEK): A$246m, +33%, 47% of group. **Equipment, Sales and Services (ESS):** (fluids, instruments and services with limited or no digital enablement): A$274m, +11%, 53% of group. Integrated on-site services grew 20% in FY26, from a disclosed FY25 base of A$41m. The average number of global sites rose 42%. ### Value-chain position IMDEX is a tier-one supplier to drilling contractors and a technology and data partner to resource owners. It does not own drill rigs. Its products sit inside the drilling process: - fluids in the hole; - survey and orientation instruments on the core barrel and downhole; - directional drilling tools (DeviDrill); - blast-hole sensors in production (IMDEX Mining Technologies, IMT); - software that consumes this data (HUB-IQ, ioGAS, aiSIRIS, Datarock, EarthNET, WellCAD, Krux). Two features are strategically important. First, the drilling contractor is often the paying customer and the resource company is the data owner. Second, IMDEX increasingly sells "integrated" packages across both. ### Customer types and end-markets | Customer / end-market | Description | Evidence | |---|---|---| | Drilling contractors | 150+ contractors; rental and fluids buyers | FY26 Annual Report | | Resource companies (majors, mid-tiers, juniors) | 500+ companies; buyers of software, advisory, DCD and integrated solutions | FY26 Annual Report | | Exploration (greenfield / brownfield / near-mine) | Core market; ~75% of global exploration spend is gold and copper | FY24 Results Announcement | | Mining production | IMT (blast-hole and underground sensors); revenue +32% in FY26 | FY26 Results Presentation | | Adjacent earth sciences | Civil/infrastructure (strong in Germany in FY26), geotechnical, groundwater, environmental, energy; expanded through ALT/MSI | FY26 Results Presentation; ALT/MSI announcement (1 Dec 2025) | ### Independent characterisation IMDEX is best understood as a high-margin "picks-and-shovels" consumables and rental franchise, with a nascent software layer. The economic engine remains the rental fleet and fluids. These are cyclical, but defended by patents (core orientation has been litigated successfully in Australia, the US, Canada and South Africa), by a global service network, and by switching costs created by HUB-IQ data integration. The FY26 acquisitions raise digital exposure, but software and advisory is still only ~4% of revenue. The "platform" label (47%) is driven overwhelmingly by connected rental hardware. The equity story therefore rests on three things: - sustaining share-of-wallet gains (A$2.40 per A$100 of exploration spend in FY26, up from A$2.20); - converting the connected fleet into recurring software revenue; - diversifying into production and non-mining earth-science markets to dampen exploration cyclicality.

Revenue$0.3B
Employees851
Market CapN/A
Founded1980
Balcatta, Australia
Imagion

Imagion Biosystems Limited

Premium
Information Technology

Imagion Biosystems is a clinical-stage medical imaging company seeking to introduce molecular specificity to magnetic resonance imaging (MRI) without radioactivity. Its MagSense® platform uses bio-safe superparamagnetic iron oxide nanoparticles conjugated to targeting moieties, such as antibodies, so that MRI contrast changes appear only where a target biomarker—initially HER2 on breast cancer cells—is present. The lead candidate, the MagSense® HER2 Imaging Agent, completed a first-in-human Phase 1 study in Australia in 2023 and received US FDA IND clearance in June 2026 for a three-part, multi-site Phase 1b/2 trial in HER2-positive breast cancer patients with suspected nodal involvement. Siemens Healthineers and Wayne State University support protocol optimisation. Prostate and ovarian agents sit in preclinical stage, contingent on funding. Commercially, Imagion is pre-revenue, has negative shareholders' equity, depends on frequent dilutive placements and a convertible note facility, and carries a going-concern material uncertainty. It is a binary, catalyst-driven micro-cap. --- ### Company's own description In its FY2025 Annual Report, the company describes its principal continuing activities as "Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance." The Executive Chairman's letter frames 2025 as the year Imagion "returned to its mission of developing the world's first molecular MRI imaging technology," re-established the development plan for the MagSense® HER2 imaging agent, and filed its first IND with the US FDA. Company boilerplate describes Imagion as a clinical-stage medical imaging company dedicated to transforming how cancer is diagnosed and treated, through MagSense®, a first-of-its-class MRI imaging agent intended to let clinicians detect cancer earlier and with greater precision. ### How the technology works MagSense® agents consist of iron oxide nanoparticle cores (historically described as approximately 25 nm with a specialised polymer coating) conjugated to custom targeting moieties such as antibodies. After intravenous injection, the particles accumulate at cells expressing the target biomarker. Under MRI, the presence of iron oxide produces a marked, identifiable change in image contrast. Management contrasts this with general-purpose gadolinium contrast agents, which distribute broadly and highlight vascularity rather than molecular identity. The company positions the approach as non-radioactive, in contrast to PET/SPECT molecular imaging. The lead clinical use case is staging of HER2-positive breast cancer: determining whether cancer has spread to axillary lymph nodes, which drives surgical and systemic-therapy decisions. Current practice relies on ultrasound, biopsy and surgical sentinel lymph node biopsy. Imagion argues that a molecular MRI read could reduce invasive procedures and could potentially image response following neoadjuvant (pre-surgical) therapy. ### Evolution of the platform At IPO in 2017, "MagSense" referred to a superparamagnetic relaxometry (SPMR) system: a dedicated magnetic-sensor instrument paired with targeted nanoparticles. The prospectus-era business model envisaged an installed base of MagSense instruments generating high-margin recurring consumable revenue. The company later pivoted to using conventional clinical MRI scanners as the detection modality. This was a material strategic change: it removed the need to build and regulate a capital instrument and shifted regulatory classification towards an imaging agent (drug/biologic pathway, IND) rather than a device-plus-test (IDE pathway, for which an FDA Breakthrough Device designation had been obtained for the MagSense System and Test for staging HER2 breast cancer). ### Business model and revenue model | Revenue model element | Status | Evidence | |---|---|---| | Product sales (imaging agents) | Pre-commercial; no product approved | FY2025 Annual Report | | Nanoparticle contract sales (research-use iron oxide nanoparticles) | Material in FY2023–FY2024 (A$1.27M receipts in FY2023; A$1.16M sale of goods in FY2024); nil in FY2025 after manufacturing footprint was closed | FY2023 Prelim; FY2025 Annual Report Note 5 | | Licensing (PrecisionMRX®) | Licence to Biosensis (2024) for research-market manufacture and sale under Imagion's PrecisionMRX® trademark; milestones and royalties on net sales. No royalty revenue separately disclosed in FY2025. | Q3 FY2024 quarterly (28 October 2024) | | Government incentives | Australian R&D Tax Incentive (A$3.53M received in 2023 for 2022; A$0.44M recognised FY2024; A$0.04M FY2025) and small grants | FY2023 Prelim; FY2025 Annual Report | | Future model (management intent) | Commercialisation of MagSense® agents directly or via partnering/licensing with imaging/pharma companies; potential AI-enabled quantitative image interpretation tools | Stockhead/company releases 2025–2026 | Revenue mix in FY2025: 0% product, 0% service, 0% subscription, 0% licensing; the A$73,031 of "revenue and other income" comprised interest income (A$32,369) and R&D tax incentive (A$40,662). In H1 2026, "revenue and other income" of A$525,934 was almost entirely a non-cash accounting gain on modification of convertible notes (A$524,897). ### Value-chain position, customers and end-markets Imagion sits at the discovery/clinical development stage of the diagnostic imaging agent value chain. Upstream it depends on contract manufacturers and antibody supply (manufacturers not named in reviewed filings); downstream it would sell to (or through) hospital radiology departments, breast imaging centres and imaging-agent distributors, ultimately reimbursed by payers. Its adjacency partners are MRI equipment vendors (Siemens Healthineers collaboration). Historical paying customers were research and industrial buyers of nanoparticles, including New Phase (Israel), which used particles for exploratory SaNP hyperthermia therapy. End-markets targeted: (i) HER2-positive breast cancer staging and treatment-response imaging; (ii) prostate cancer detection/characterisation; (iii) ovarian cancer detection; (iv) exploratory brain (glioblastoma) and pancreatic cancer imaging via collaborations. ### Independent characterisation Imagion is best characterised as a single-asset, platform-optionality micro-cap biotech. Its scientific premise—targeted iron oxide nanoparticles as MRI molecular probes—is established in the academic literature, and its execution has advanced to a cleared US IND. The commercial question is whether a non-radioactive molecular MRI agent can achieve diagnostic accuracy and workflow economics competitive with sentinel node biopsy, ultrasound-guided biopsy, PET-based molecular imaging and surgical magnetic tracers. The financial reality is acute: the balance sheet showed net liabilities of A$3.42 million at 30 June 2026, cash of A$32,456 at that date (before approx. A$3.73 million of placement proceeds received July–August 2026), and convertible notes maturing in late 2026 with a conversion floor well above the prevailing share price.

RevenueN/A
Employees19
Market Cap$0.0B
Founded2016
Melbourne, Australia
ikeGPS

ikeGPS Group Limited

Premium
Information Technology

| Item | Detail | |---|---| | Legal name | ikeGPS Group Limited | | Former names | Surveylab Group Limited (renamed ikeGPS Group Limited in October 2013, per investing.com company profile) | | Founding year | 2003 (company incorporation date reported as 17 April 2003 by IBISWorld; founder Leon Toorenburg) | | Incorporation jurisdiction | New Zealand | | Registered office (NZ) | Level 2, 79 Boulcott Street, Wellington Central 6011, New Zealand (NZX company profile) | | Operating headquarters (US) | 329 Interlocken Parkway, Suite 120, Broomfield, Colorado 80021, USA (address on July 2025 release; earlier releases cite 350 Interlocken Blvd, Suite 390) | | Exchanges & tickers | NZX Main Board: IKE (primary; first listed 23 July 2014); ASX: IKE (dual listing in place by at least September 2019); OTC (US): IKGPF | | ISIN / CUSIP | NZ-domiciled issuer) | | Fiscal year end | 31 March | | Employees | ~85 (latest aggregator data, investing.com / Kalkine, 2026); 3-year trend not publicly disclosed in sources reviewed | | Auditor | Grant Thornton (NZX company profile; confirmed present at 2025 AGM) | | Legal adviser | Chapman Tripp | | Share registry | MUFG Pension & Market Services (formerly Link Market Services) | | Shares on issue | ~194.1m (Forsyth Barr, 2 June 2026) | | Market capitalisation | ~A$175m on ASX at A$0.91–0.93 (late Aug–early Sep 2026); NZ$226m at NZ$1.17 on NZX (29 May 2026). | | Net cash | NZ$33.8m cash, nil debt, 30 June 2026 (1Q FY27 update) | | Website | www.ikegps.com | | Investor relations | Simon Hinsley (NWR Communications); company secretary/finance contact James Macdonald | No name change or listing move has occurred since the 2013 rename. ikeGPS (trading as "IKE", self-styled "the PoleOS Company") is a vertical software company that digitises, analyses and manages data on overhead utility poles and attached assets for North American electric utilities, communications carriers and the engineering service providers that work for them. Originating as a New Zealand rugged-measurement hardware maker, IKE has pivoted over a decade into a subscription-led platform that spans field capture (IKE Device and IKE Office Pro), structural/pole-loading analysis (IKE PoleForeman), AI automation (PolePilot, IKE Insight), outsourced analysis (IKE Analyze) and NESC/OSHA training (IKE University). Platform subscriptions were 72% of FY2026 revenue at a ~94% gross margin, and the company claims standardisation inside eight of the ten largest North American investor-owned utilities. With NZ$33.8m net cash, positive underlying EBITDA reached in March 2026, and three new modules due in 2H FY2027, IKE is positioned as a small-cap, pure-play software beneficiary of the US distribution-grid modernisation and fibre/5G attachment cycles. --- ### What the company does IKE sells an integrated workflow for the life cycle of a distribution pole. A single wooden pole may carry electric primaries and secondaries, transformers, streetlights, fibre and coaxial cable owned by several parties. Every new attachment (fibre, 5G small cell), every grid-hardening project, and every inspection triggers a need to know precisely what is on the pole, at what height, whether clearances comply with the National Electrical Safety Code (NESC), and whether the pole can bear additional load. IKE's platform covers each step: 1. **Capture** — The IKE Device (calibrated camera, laser rangefinder, GPS/RTK) lets a single field technician measure heights and attachments from a distance, with guided forms producing a structured record. 2. **Digitise and manage** — IKE Office Pro, a cloud application, lets back-office analysts measure attachments, perform QA, map and export the data; PolePilot (an AI module launched late 2025) automates identification and height annotation of wires and equipment. 3. **Analyse and engineer** — IKE PoleForeman performs pole-loading and structural analysis (spans, line angles, wire sizes, strength utilisation, clearances) for NESC compliance and make-ready engineering. 4. **Outsourced processing** — IKE Analyze, a tech-enabled service, processes customer imagery into heights of attachment, load analysis and make-ready recommendations on a per-pole (transaction) basis. 5. **Automate at scale** — IKE Insight, built on the acquired Visual Globe AI assets, applies machine learning to large existing imagery datasets (e.g., double-pole detection, joint-use ticket preparation). 6. **Educate** — IKE University and NESC/OSHA training programmes (webinars and in-person certification). ### Company's own description (latest annual report and releases) In its FY2025/FY2026 releases the company describes itself as aiming to become the standard for collecting, digitising, analysing and managing pole and overhead asset information for electric utilities, communications companies and their engineering service providers, enabling them to improve speed, quality and safety in building and maintaining distribution assets. Its 2026 AGM materials frame a ten-year mission (to mid-2034): to be the most trusted software provider driving productivity in the distribution grid, with the number-one market share in the USA and expansion internationally. The company's stated purpose is the Māori concept *Manaakitanga* ("we rise by lifting others"). ### Business and revenue model | Revenue stream | Nature | FY2026 revenue (NZ$m) | Share of FY2026 revenue | FY2026 gross margin | |---|---|---|---|---| | Platform Subscription | Annual/multi-year SaaS seat licences (Office Pro, PoleForeman, PolePilot, Insight) and Device-as-a-Service | 19.2 | 72% | ~94% | | Platform Transaction | Per-pole processing via IKE Analyze (tech-enabled services) | 5.0 | 19% | ~34% | | Hardware & Other | IKE Device sales, training (IKE University), other services | 2.4 | 9% | ~67% | | Total | — | 26.5–26.6 | 100% | ~80% | Sources: FY2026 results release (29 May 2026); Forsyth Barr FY26 review (2 June 2026). The company reports that ~91% of FY2026 revenue came from recurring (subscription) and re-occurring (transaction) sources (2026 AGM presentation). The core commercial engine is enterprise subscription customers × seats × price, with expansion via cross-sell (Office Pro → PoleForeman → PolePilot) and AI-led price increases (PolePilot enabled a ~10% price rise across the Office Pro base with no reported churn). ### Value chain position IKE sits in the engineering-software and data layer of the utility/telecom capital-works value chain: downstream of field-collection hardware (where it also competes), upstream of utility GIS, asset-management and permitting systems (into which it exports), and adjacent to engineering service providers (ESPs) who are both customers and channel. It does not perform physical construction or pole replacement. ### Customer types and end-markets | Customer type | Examples disclosed (company materials / third-party profiles) | Role | |---|---|---| | Investor-owned electric utilities (IOUs) | Company cites 8 of the 10 largest North American IOUs; 2026 AGM slide names Exelon, Southern Company, Florida Power & Light, National Grid, Entergy, Consumers Energy, Duke Energy among its top eight (~43m customer premises) | Primary subscription buyers (standards-driven) | | Communications carriers | 5 of the 10 largest US communications companies; AT&T, Crown Castle, Corning Optical Communications, ALLO Communications named in public materials | Fibre/5G attachment and make-ready | | Engineering service providers | TWiG Technologies, Cyient, Horrocks, Luck Grove, TRC | Heavy users of devices, Office Pro and PoleForeman | | Municipal utilities & cooperatives | >2,800 municipalities and co-ops identified as a sales opportunity (2026 AGM) | Largely untapped "green field" | **Independent characterisation:** IKE is best understood as a niche vertical SaaS company whose moat rests on workflow embedding in utility engineering standards (once a utility mandates PoleForeman for its distribution design, every contractor engineering on its network needs seats), a proprietary dataset (company claims ~20 million engineered overhead assets), and NESC domain credibility (an IKE employee, Grant Glause, sits on the NESC main committee). Its weakness is scale: at ~NZ$26.6m revenue it is small against diversified engineering-software incumbents, and its lower-margin transaction business is exposed to lumpy telecom project cycles.

Revenue$0.0B
Employees85
Market CapN/A
Founded2003
Wellington Central, New Zealand
IHSHolding

IHS Holding Limited

Premium
Information Technology

IHS Towers is one of the world's largest independent owners, operators and developers of shared passive telecommunications infrastructure by tower count. It is also Africa's largest independent towerco, and it has always focused only on emerging markets. The business leases vertical space and power/ancillary capacity on ~28,000+ towers in five African markets (Nigeria, South Africa, Côte d'Ivoire, Cameroon and Zambia) under long-term, inflation- and FX-linked master lease agreements, primarily with MTN, Airtel, Orange and Telkom. Nigeria, with more than 16,000 towers, is the economic core and generated about two-thirds of FY2025 continuing revenue. After a turbulent public life marked by Naira devaluation, multi-billion-dollar FX finance losses and governance disputes with major shareholders, IHS ran a strategic review from 2024 to 2026. The review sold Kuwait, Peru, Rwanda, I-Systems and the Latam towers, cut net leverage to 2.8x, and culminated in an agreed USD 6.2bn take-private by its largest customer and shareholder, MTN. --- ### What the company does IHS builds, acquires, owns and operates passive telecom infrastructure: steel lattice and monopole towers, rooftop sites, small cells/in-building solutions, and the associated power systems (diesel generators, batteries, solar hybrid systems, grid connections). Mobile network operators (MNOs) rent space and power on these sites for their active radio equipment under multi-year master lease agreements (MLAs). Until May 2026 IHS also owned a 51% stake in I-Systems, a shared fiber network in Brazil. It has also developed fiber and other "adjacent verticals" in Nigeria. ### Business and revenue model The model is a classic towerco annuity: **Lease revenue (tenancy):** the main revenue stream. Each site generates a base fee per tenant. Colocation (adding a second or third tenant) is highly accretive because site costs are largely fixed. The colocation rate was 1.46x at FY2025 end and 1.47x at Q2 2026. **Lease amendments:** incremental fees when tenants add equipment, height, power or new technologies such as 4G/5G radios. Lease amendments reached 43,999 at FY2025 end, up 4,328 year on year. **New sites (build-to-suit):** greenfield towers built to MNO specification, usually with an anchor-tenant commitment. **Power and managed services:** in Nigeria and other African markets, IHS provides power to tenants and recovers diesel/power costs through power-indexed fee components. In South Africa it provides power Managed Services to MTN SA on about 13,000 sites under the 2022 deal. **Contract protection mechanisms:** MLAs include CPI escalators and, crucially in Nigeria, partial USD-linkage and FX resets that re-price portions of Naira fees as the currency moves. They also include power indexation tied to diesel prices. These mechanisms recovered a large share of devaluation losses in 2023–2025, but with a lag. The revenue mix is overwhelmingly contracted, recurring service/lease income. There is effectively no product sale or licensing revenue. Customer concentration is extreme: MTN is the dominant customer, especially in Nigeria and South Africa, followed by Airtel and Orange. ### Value-chain position IHS sits between tower/equipment suppliers and power/diesel suppliers on one side and MNOs on the other. Its value-add is capital provision (MNOs monetise towers through sale-and-leasebacks), operational excellence in harsh power environments (grid-unreliable markets where diesel logistics, security and uptime SLAs are core skills), and neutral-host sharing economics. ### Customers and end-markets | Customer type | Examples (as disclosed / reported) | Notes | |---|---|---| | Tier-1 MNOs (Key Customers) | MTN (Nigeria, South Africa, Cameroon, Côte d'Ivoire, Zambia; formerly Rwanda), Airtel (Nigeria, Zambia), Orange (Côte d'Ivoire, Cameroon) | MTN Nigeria contracts renewed and extended in Q3 2024; Airtel renewed in 2024 | | Smaller MNOs | T2 (formerly 9mobile), Nigeria, described as the "smallest Key Customer" | Updated agreement Q3 2025: T2 vacates sites and settles overdue balances through July 2027 | | Fixed/converged operators | Telkom SA | MLA renewed and extended for 5 years from 1 Jan 2026 | | Former Latam customers | Telefônica Brasil (Vivo), Claro, TIM, Oi | Exited Aug 2026 | | Other | ISPs, government/enterprise connectivity, fiber customers in Nigeria | Not separately quantified | ### The company's own description IHS describes itself, in its standard press-release boilerplate (FY2025 and 2026 releases), as one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count, focused solely on emerging markets. After the Latam exit it reports more than 28,000 towers across five markets: Cameroon, Côte d'Ivoire, Nigeria, South Africa and Zambia. ### Independent characterisation Analytically, IHS in late 2026 is a pure-play African towerco and a Nigeria-concentrated FX-risk vehicle whose public-market story is ending. Its operating economics are sound: segment Adjusted EBITDA margins were ~63% in Nigeria and ~57% in SSA in Q4 2025, ALFCF was USD 448m in FY2025, and leverage has fallen. But the equity was destroyed in 2022–2024 by three forces. First, translation and finance losses from the Naira's collapse (from ₦775.6/USD in Sept 2023 to ₦1,669.1/USD in Sept 2024). Second, an expensive, debt-funded diversification into Latin America and Kuwait that the market never rewarded. Third, governance friction with its two largest shareholders. The MTN take-private reverses the original sale-and-leaseback arrangement: Africa's largest MNO buys back the towers it sold to IHS over the past decade. The independent-towerco model in Nigeria thereby gives way to an operator-owned "infraco" subject to regulatory non-exclusivity conditions.

RevenueN/A
Employees2,762
Market Cap$2.9B
Founded2001
London, United Kingdom
IGO

IGO Limited

Premium
Information Technology

IGO Limited is an ASX-listed, Perth-based critical-minerals company in the middle of a deliberate transition from a nickel producer with a lithium investment into a lithium-and-copper growth company. Its earnings anchor is a 24.99% indirect interest in Greenbushes, held through its 49% stake in the Tianqi-controlled TLEA joint venture. Greenbushes is widely regarded as the world's highest-grade, lowest-cost hard-rock lithium mine and, according to Bloomberg Intelligence (via Mining Weekly, April 2026), accounts for roughly a fifth of global lithium output. The wholly owned Nova nickel-copper-cobalt mine, IGO's only operated asset, reaches end of life in the December 2026 quarter and is being sold to Global Lithium Resources. Kwinana, the 49%-owned lithium hydroxide refinery, has been fully impaired. IGO's next chapter rests on a net-cash balance sheet of A$387M, proprietary BioHeap™ copper bioleaching technology, a rationalised exploration portfolio (WA, NT, SA, Arizona), and an ambition to build a copper business at scale by 2035. --- ### Company's own description (Annual Report 2026, paraphrased) IGO describes itself as an ASX-listed company focused on discovering, developing and delivering the critical minerals needed for electrification. Its stated purpose is "Making a Difference." Its strategy is to become a globally relevant supplier of critical raw materials through a diversified portfolio primarily focused on lithium and copper. That strategy is underpinned by technical and exploration capability, proprietary processing technology (BioHeap™), and development through strategic partnerships. Lithium is described as the portfolio's foundation, anchored by Greenbushes. Copper is named as the "primary growth commodity." ### Business model and value-chain position | Engine | Ownership / control | How value reaches IGO | Value-chain position | |---|---|---|---| | Nova Operation (Ni-Cu-Co) | 100%, operated by IGO (underground mining contractor Barminco) | Consolidated revenue from concentrate sales (FY26: A$448.9M) | Upstream: mining and concentrating; concentrate sold to smelters/traders under offtake (counterparties ND in sources reviewed) | | Greenbushes (spodumene) | 24.99% indirect: IGO 49% of TLEA → TLEA 51% of Windfield Holdings → Talison Lithium (operator); Albemarle holds 49% of Windfield | Equity-accounted share of TLEA profit; cash only via TLEA dividends (none received in FY26) | Upstream: hard-rock mining and spodumene concentration; product sold to the owners (Tianqi and Albemarle) | | Kwinana Refinery (LiOH) | 49% via TLEA (100% TLEA-owned, operated by Tianqi Lithium Kwinana) | Equity-accounted share of losses; asset fully impaired at 30 June 2025 | Midstream: chemical conversion of spodumene to battery-grade lithium hydroxide monohydrate | | Growth (exploration, BioHeap™, business development) | 100% or JV-earning | Option value; no revenue | Discovery and technology | IGO's FY26 annual report lists seven business activities: exploration and discovery, project development, mining, processing (including BioHeap™), participation through joint-venture partners, market and delivery, and mine transition. In practice, the economic model in FY26 had three distinct engines: ### Revenue model mix The revenue model is 100% physical commodity sales (product), with no service, subscription or licensing revenue. BioHeap™ is a potential future licensing or partnering platform but generates no disclosed revenue. In FY26, Nova concentrate sales made up about 97% of reported revenue (A$448.9M of A$462.9M; the remainder is other/corporate revenue, composition ND). This makes the consolidated revenue line a nickel-business line. The lithium economics sit below revenue in the equity-accounted TLEA result (A$207.3M in FY26). ### Customer types and end-markets **Nickel/copper/cobalt concentrate:** smelters and refiners serving stainless steel, battery precursor (nickel sulphate) and copper markets. Specific offtakers are ND in the FY26 materials reviewed. **Spodumene concentrate (Greenbushes):** sold to the joint-venture owners Tianqi Lithium and Albemarle, who convert it into lithium carbonate or hydroxide for EV and energy-storage battery cathodes. Technical-grade concentrate serves glass and ceramics. **Lithium hydroxide (Kwinana):** battery cathode makers. 99.1% of FY26 output met battery-grade specifications, and TLK continued to qualify product with new customers (Annual Report 2026). ### Independent characterisation IGO is best understood today as a listed, cash-backed holding vehicle for a minority, non-operated stake in a Tier-1 lithium mine, with a self-liquidating nickel asset and an early-stage copper growth option. The company has limited control over its most valuable asset. Greenbushes' operating decisions sit with Talison, and Kwinana's with Tianqi, its 51% partner in TLEA. As a result, IGO's cash returns depend on TLEA dividend policy, which in turn depends on a partner whose strategic interests (security of supply for its Chinese conversion assets) differ from IGO's (return on capital). The Kwinana disagreement shows this tension most clearly. After Nova closes, IGO will have no consolidated operating revenue. Its P&L will become equity-accounted lithium earnings, minus corporate and exploration costs. Investors will therefore value IGO as a geared, minority look-through on Greenbushes plus cash plus copper optionality.

Revenue$0.3B
Employees358
Market CapN/A
Founded2000
South Perth, Australia
Ignite

Ignite Limited

Premium
Information Technology

Ignite Limited is a micro-cap Australian specialist recruitment firm whose economic engine is the supply of contingent (temporary/contract) labour to Australian Federal Government agencies, concentrated in three disciplines: Technology, Engineering and Business Support. Founded in Sydney in 1984 as Candle, it is one of the longest-established IT recruitment brands in the country, and its top 20 Federal Government clients have, according to the company, worked with it for an average of more than three decades. Following a severe downsizing between FY22 and FY24, a 2023 recapitalisation and a 2024 share consolidation, the business has been rebuilt as a lean, debt-free, cash-generative operation of roughly 34 internal staff. FY26 revenue was A$73.2m with a gross margin near 13%. With A$6.7m of cash against a market value of roughly A$12m, large carried-forward tax losses and substantial franking credits, Ignite is effectively a small, high-payout, government-exposed labour-hire annuity searching for accretive acquisitions. --- ### What the company does Ignite's principal activities, as defined in the 2026 Directors' Report, are the provision of contingent labour and permanent placement services (collectively "Specialist Recruitment") and, until its closure during FY26, a small Technology Solutions business. The company states that it operates nationally and employs approximately 34 permanent staff. In its 2026 Chair's Letter and Executive Director's Report, management characterises Specialist Recruitment as the core business, composed largely of Federal Government clients, contributing more than 99% of gross margin, with the core disciplines being Technology, Engineering and Business Support. The company also highlights long client relationships (top 20 Federal Government clients averaging more than 30 years) and long account-manager tenure (average more than 10 years), along with a 4.9-star Google rating and 4.5-star Glassdoor rating. ### Business model and revenue model | Revenue stream (FY26) | A$000 | % of revenue | Recognition | Nature | |---|---|---|---|---| | Contingent labour | 71,911 | 98.2% | Over time, gross (principal) basis | Ignite engages contractors and on-bills their time to clients at a marked-up rate | | Permanent recruitment | 901 | 1.2% | Point in time, on candidate commencement | Success fee for permanent, part-time or fixed-term placements | | Technology Solutions | 381 | 0.5% | Over time | Project/managed IT services; business closed during FY26 | | Total | 73,193 | 100.0% | — | — | Ignite's revenue model is overwhelmingly a service/time-and-materials model with no product, subscription or licensing revenue: Source: 2026 Annual Report, Note 5. **Economics.** Because contingent labour is booked gross (the business is judged to act as principal: it contracts directly with the contractor, carries primary responsibility for service delivery and has latitude to set rates), headline revenue overstates the economic value-add. The more meaningful line is gross profit (net fee income) — A$9.42m in FY26 — which equals revenue less contractor pay and on-costs (A$63.8m). Gross margin has been held at roughly 12.9–13.0% for two years, up from 11.5% in FY23, reflecting deliberate "margin mix" management (2025 Half Year Report). **Working-capital model.** Federal agencies pay on standard terms, and Ignite pays contractors weekly/fortnightly; the gap is funded from operating cash, with an undrawn debtor finance facility available as a backstop (2026 Annual Report, Note 4). ### Value-chain position Ignite sits in the intermediary layer between government buyers of skilled labour and individual specialist contractors. Access to Federal Government demand typically runs through procurement panels and preferred-supplier arrangements; the company references preferred supplier agreements that dictate longer payment terms (2026 Annual Report, Note 4(b)). Specific panel memberships are not itemised in the reviewed filings. ### Customer types and end-markets | Dimension | Characterisation | Evidence | |---|---|---| | Primary customer | Australian Federal Government departments and agencies | 2026 Chair's Letter | | Concentration | Four largest customers = A$25.33m (34.6% of revenue) in FY26; largest = A$8.97m (12.3%) | 2026 Annual Report, Note 6(b) | | Geography | 100% of trade receivables from Australian customers (FY25 and FY26) | 2026 Annual Report, Note 4(b) | | Disciplines | Technology (IT/digital), Engineering, Business Support | 2026 Annual Report | | Historic disciplines | Information management (records, archives, library), finance, professional services | RIMPA listing; Yahoo Finance profile | **Independent characterisation.** Ignite is best understood as a niche, Canberra-centric government labour-hire provider with a Sydney head office, whose fortunes are tied to Federal Government policy on external labour. It is no longer a diversified recruiter: the China, Singapore/Hong Kong (Lloyd Morgan), New Zealand trading, "On Demand", "People Services" and Technology Solutions operations of the Clarius era have all been exited. What remains is a sub-scale but profitable fee stream, a clean balance sheet and significant tax assets.

Revenue$0.0B
Employees34
Market CapN/A
Founded1984
North Sydney, Australia
iCetana

iCetana Limited

Premium
Information Technology

| Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Reported headcount (persons) | n/d | n/d | n/d | | Employee benefits expense (A$'000) | n/d | 3483 | 4224 | Only Perth headcount was disclosed (17 in July 2024, per techpartner.news). Employee benefits expense rose 21% in FY26, consistent with hiring in sales and marketing after the May 2026 placement. icetana AI is a Perth-based micro-cap software company that commercialises a Curtin University-originated, self-learning anomaly-detection engine for large-scale video-surveillance networks. Unlike rules-based video analytics, the core product learns the normal motion patterns of each fixed camera and surfaces only unusual events in real time. This lets control-room operators supervise thousands of cameras without manual rule configuration. The company has moved almost entirely to SaaS and maintenance revenue: about 98% of FY26 revenue was recurring. Its customers concentrate in Middle Eastern shopping-mall operators (anchor customer Majid Al Futtaim since 2016), Australian universities and retail, and Japanese enterprise buyers. Since June 2025 its growth strategy has been tied to a cornerstone partnership with SoftBank Robotics Group, which is now its largest strategic shareholder, distributor across five regions, and board nominee. Japanese distributor and shareholder Macnica adds further reach. With FY26 revenue of A$2.47m, ARR of A$2.6m and a net loss of A$3.66m, icetana remains a sub-scale, loss-making, cash-consuming business in a crowded global market. --- ### Company's own description (paraphrased from FY26 Directors' Report) The FY26 Annual Report describes the principal activity as developing and selling AI-assisted video-surveillance software. The software uses machine learning to detect anomalous events automatically and in real time. According to the Directors' Report: - icetana was founded in 2009 to commercialise Curtin University research on efficiently analysing very large data sets to find activity outside normal patterns. - The software builds a model of "normal" movement for each fixed-field-of-view camera during a learning phase. It then flags unusual movement or activity in real time through an interface that highlights the anomalous events. - Operators in security operations centres, who may be responsible for hundreds or thousands of cameras, review the flagged events and decide on a response. - The solution either integrates with existing video management systems (VMS) or connects directly to camera feeds. - Stated use cases are security, loss prevention, theft, and health and safety. - The company plans to target further verticals such as prisons, healthcare and guarding services. - The business has moved mostly to SaaS, supplemented by a direct-licensing model with recurring maintenance fees for customers or markets that prefer upfront licences. ### Business model and revenue model | Revenue stream | Description | FY2025 (A$'000) | FY2026 (A$'000) | Source | |---|---|---|---|---| | Recurring revenue | SaaS subscriptions (typically billed 12 months in advance; multi-year contracts of 36–60 months) plus maintenance on perpetual licences | 1805 | 2425 | FY26 AR Note 4 | | Enterprise revenue | One-off licences, implementation, hardware | 83 | 49 | FY26 AR Note 4 | | Total | — | 1888 | 2474 | FY26 AR Note 4 | **Mix:** Recurring revenue was about 98% of FY26 revenue (FY25: about 96%) (FY26 Directors' Report). FY24 was the exception. That year included a roughly A$1.5m one-off sale of AI hardware to the main Middle East customer, which inflated revenue to A$3.7m (techpartner.news, 30 Aug 2024). **Billing:** Customers usually prepay annual subscriptions, so unearned revenue is a meaningful liability. It stood at A$2.30m at 30 June 2026, up from A$1.66m a year earlier (FY26 AR Note 12). This is a forward revenue cushion of about 0.93x FY26 revenue. **Channel:** The company sells mainly through partners and distributors: - SoftBank Robotics Group (Japan, Australia/NZ, broader APAC, Middle East, Americas) - Macnica (Japan) - Regional resellers and integrators such as NIT (Middle East) and HTE Electronics Trading LLC (Iraq) - VMS ecosystem partners (Genetec, Milestone, Axis) Direct enterprise sales remain important for anchor accounts. **Key operating KPIs:** Annualised recurring revenue (ARR) and net ARR retention. - ARR was A$2.6m at 30 June 2026, up 33% year on year (Q4 FY26 report). - Net ARR retention was 100% in Q4 FY26, down from 108% in Q3 FY26 (Q4 FY26 report, which states an 8-point QoQ decrease). ### Value-chain position icetana sits in the analytics software layer of the physical-security technology stack, between: **Upstream:** camera hardware (Axis, Hanwha, Hikvision, etc.) and VMS platforms (Genetec, Milestone) **Downstream:** systems integrators, guarding and facilities-services companies (for example Millennium Services Group) and end-user security operations centres. It does not make cameras or VMS. It occasionally resells AI compute hardware as part of deployments. The FY24 hardware sale and the "product manufacturing and operating costs" line in Appendix 4C reflect this. ### Customer types and end-markets | Vertical (as reported) | FY2025 revenue (A$'000) | FY2026 revenue (A$'000) | Growth % | Example customers (public) | |---|---|---|---|---| | Retail | 668 | 879 | 31.6 | Majid Al Futtaim (16 malls, Middle East); Tamdeen Mall Management (Kuwait); 1 Utama (Malaysia); Queensland shopping centre via Millennium | | Education | 217 | 209 | -3.7 | Curtin University (3-year A$242k renewal, 2026) | | Commercial and other | 1003 | 1386 | 38.2 | SoftBank Robotics channel customers in Japan; a Japanese utility (via Macnica); casinos; transport; government/safe city | | Total | 1888 | 2474 | 31.0 | — | Source: FY26 Annual Report Note 4; ASX announcements 10 Mar 2026, 3 Apr 2023, 24 Oct 2025, 28 Apr 2025. ### Independent characterisation icetana is effectively a single-product, platform-in-transition company. The legacy anomaly-detection engine has been in the market for over a decade. It is now being extended with: - object- and event-specific detectors (licence plate recognition, facial recognition, line crossing, occupancy, floor hazards) - an on-premise generative-AI engine (Antara Core, released Q3 FY26) - "agentic" triage capabilities. Commercially, the company has been small for its age. Revenue was below A$2m in every year from FY18 to FY23, apart from the hardware-boosted FY24. It has historically depended on a few Middle Eastern mall operators, with MAF the largest customer. The June 2025 SoftBank Robotics partnership changed both the shareholder register and the distribution model. Growth now depends largely on how well SoftBank's regional subsidiaries convert icetana into recurring revenue, and on cross-selling Antara Core into SoftBank-linked entities such as Millennium Services Group.

Revenue$0.0B
Employees17
Market CapN/A
Founded2009
Perth, Australia

Page 106 of 482

1…105106107…482

Page 106 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo